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ABSTRACT 
 
 
 
With rapid emergence of antibiotic resistance, there is a pressing need for a new 
generation of anti-infective agents with a less likelihood of developing resistance. 
Antimicrobial peptides are regarded as promising therapeutic alternatives with desirable 
antimicrobial activities, favorable biological functions, and a low chance to develop 
resistance. Defensins and cathelicidins comprise two major families of cationic 
antimicrobial peptides in vertebrate animals. Recent availability of the chicken genome 
sequence provides an excellent opportunity to search for novel antimicrobial peptides 
with therapeutic potential. In this report, a genome-wide computational screen of the 
entire chicken genome led to identification of a gene cluster on chromosome 3q3.5-q3.7 
containing thirteen different β-defensin genes as well as a cluster on chromosome 2p 
containing three cathelicidin genes. Among all novel chicken antimicrobial peptides 
identified, two cathelicidins, which we named fowlicidin-1 and -2, were chosen to study 
for their antibacterial properties. Both fowlicidins were found to display potent and salt-
independent activities against a wide range of bacteria, including antibiotic resistant 
strains. Furthermore, both are capable of binding lipopolysaccharide (LPS) and 
neutralizing its inflammatory effects, suggesting that both peptides may be excellent 
candidates as novel antimicrobial and anti-sepsis agents. Based on the tertiary structure of 
fowlicidin-1, a series of truncation and substitution analogs were further synthesized and 
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tested for their antibacterial, cytolytic, and LPS-binding activities. A short peptide variant, 
namely fowlicidin-1(8-26), stands out with the highest therapeutic potential among all 
analogs, representing a safer and more attractive therapeutic candidate than the parent 
peptide. 
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CHAPTER I 
INTRODUCTION 
 
With rapid emergence of antibiotic-resistance pathogens in the last several decades, 
there is a pressing need for a new generation of antibiotics with a less likelihood of 
developing resistance for clinical use. One promising option to solve this problem is to 
develop cationic antimicrobial peptides as a new class of antimicrobial agents. Cationic 
antimicrobial peptides are a large group of gene-encoded molecules that have been 
discovered in all species of life, playing a critical role in innate host defense and disease 
resistance. Defensins and cathelicidins comprise two major families of antimicrobial 
peptides in vertebrate animals.  
 
A number of defensin and cathelicidin peptides have potent and broad-spectrum 
activities toward microbes including antibiotic-resistant strains through their physical 
interaction with and disruption of microbial membranes. In addition to their ability to 
directly kill a wide range of bacteria, fungi, and enveloped viruses, defensins and 
cathelicidins plays an important regulatory role in innate immunity and other biological 
processes, including chemotaxis, dendritic cell activation, LPS-binding, and sperm 
maturation. Several antimicrobial peptides with therapeutic potential have been 
developed and are currently in clinical trials. The identification and functional and 
structural analysis of novel defensins and cathelicidins from different animal species will 
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help creating understanding the innate host defense mechanisms against microbial 
challenges and provide more potential therapeutic candidates against antibiotic-resistant 
infections.  
 
The rest of this report is organized as follows: Chapter II is the literature review of 
cationic antimicrobial peptides, including their features, classification, antimicrobial 
activity, mechanisms of action, roles in innate immunity, other biological processes, and 
therapeutic potential. A genome-wide identification of a β-defensin gene cluster in the 
chicken is provided in Chapter III.  Chapter IV describes the identification and functional 
characterization of three chicken cathelicidins with potent antimicrobial activity. Chapter 
V investigates the structure-activity relationship study of fowlicidin-1, a cathelicidin 
antimicrobial peptide in chicken. The summary, challenges and future prospects are 
discussed in Chapter VI. 
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CHAPTER II 
LITERATURE REVIEW 
 
 
The discovery of penicillin in 1929 by Alexander Fleming witnessed the beginning of 
a new era of antibiotics. Since then penicillin and other antibiotics, produced at industrial 
scale, have been widely used for the treatment of bacterial infections, as well as in many 
medical procedures including surgery and chemotherapy. The availability of antibiotics 
has revolutionized modern medicine and greatly improved human health by increasing 
the average human lifespan up to 10 years [1]. However, pathogens that are resistant to 
these antibiotics have emerged quickly in recent years due to the widespread availability 
and sometimes indiscriminate uses of antibiotics. For example, more than 95% of the 
strains of Staphylococcus aureus have been reported as resistant to penicillin [2]. Besides 
medical misuse, the application of antibiotics in animal feeds to prevent infections and 
promote growth is thought to be another major reason responsible for the emergence of 
resistance [3]. 
 
Conventional antibiotics kill bacteria by different mechanisms including inhibition of 
cell wall synthesis, interference with membrane function, inhibition of DNA replication 
and/or transcription, and inhibition of protein synthesis [4]. Different types of antibiotics 
have different cellular targets. For example, penicillin and cephalosporin bind to certain 
cell wall proteins and interfere with peptidoglycan cross-linking, and nalidixic acid 
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specifically binds to the enzymes necessary for DNA synthesis [4]. Mutations on the 
single or a limited number of specific targets could lead to emergence of new bacterial 
strains that are resistant to the actions of these antibiotics.  Consequently, we are in an 
urgent need of novel drugs with different mechanism of actions than conventional 
antibiotics to combat bacterial infections in the near future.   
 
Antimicrobial peptides, an important component of innate host defense, are currently 
being actively explored as promising antibiotic alternatives. Since a report on purothionin, 
a wheat peptide with antibacterial or antifungal activities in 1972 [5], hundreds of 
antimicrobial peptides have been discovered in virtually all species of life up to date. In 
addition to direct and broad-spectrum activity against bacteria, parasites, viruses, and 
fungi, antimicrobial peptides also play a critical regulatory role in innate and adaptive 
immune responses. 
 
2.1    Features and classification of antimicrobial peptides 
 
Antimicrobial peptides share several common features, although they have diverse 
sequences and structures [6-8]. These peptides are positively charged, normally with a net 
charge of +2 ~ +10, due to the presence of lysine and/or arginine molecules. Thus they 
are generally referred to as cationic peptides. Secondly, they are all small, ranging from 
12 to 100 amino acids and are encoded by distinct genes. Thirdly, the peptides usually 
adopt amphipathic structures with hydrophilic segments being separated from 
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hydrophobic segments, which facilitate the interaction of the peptides with microbial 
membranes. 
 
Based on the structure, antimicrobial peptides can be divided into four groups, 
namely peptides with α-helical, β-sheet, loops, and extended structures [6, 9]. The α-
helical peptides are a class of the most widespread and best-studied cationic antimicrobial 
peptides. This class of peptides, such as SMAP29 [10], magainin [11], melittin [12], 
exhibit potent antimicrobial activity, but also display considerable cytotoxicity toward 
host cells. Another major class of cationic peptides is β-sheet peptides, which contain two 
or more β-sheets stabilized by 2 ~ 4 intramolecular disulfide bridges. Among all β-sheet 
peptides, there is one particular group that form the β-hairpin due to the presence of two 
disulfide bonds between the two antiparallel β-sheets, such as the horseshoe crab peptide, 
polyphemusin [13]. This group of peptides generally exhibit salt-independent 
antimicrobial activity against Gram-positive and Gram-negative bacteria [14]. The less 
commonly studied cationic peptides are loop and extended peptides. Loop peptides are 
cyclized with a single cysteine disulfide, such as cattle neutrophil bactenecin [15]. 
Extended peptides are unstructured, but normally contain a high proportion of one or two 
amino acids, e.g. proline, tryptophan or histidine [9, 16]. Bovine neutrophil peptide 
indolicidin [17] (> 38% of tryptophan) and pig intestine peptide PR-39 [18] (> 49% of 
proline) are examples of this group of antimicrobial peptides with extended structures. 
Many of these extended peptides are unstructured in aqueous solution, but adopt their 
final conformations upon interacting with membranes.  
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2.2    Defensins and cathelicidins 
 
In vertebrates, there are two major families of antimicrobial peptides, namely 
defensins and cathelicidins, based on their phylogenies. Defensins constitute a major 
family of cationic antimicrobial peptides that are widely distributed among living 
organisms [19-23]. Containing highly conserved 6 ~ 8 of cysteine residues, all defensins 
folded into 3 ~ 4 antiparallel β-sheet structures that are stabilized by 3 ~ 4 intramolecular 
disulfide bonds with or without an α-helix. Plant defensins are characterized by 
containing eight conserved cysteine residues forming four intramoleclar disulfide bridges 
between Cys1–Cys8, Cys2–Cys5, Cys3–Cys6, and Cys4–Cys7. The cysteine pairings in 
invertebrate defensins are Cys1–Cys4, Cys2–Cys5, and Cys3–Cys6. In vertebrates, 
defensins contain a six-cysteine motif and are classified into three subfamilies, α-, β-, and 
θ-defensins, based on different disulfide bonding pattern (Figure 1). The cysteine pairings 
in α-defensins are Cys1–Cys6, Cys2–Cys4, and Cys3–Cys5, while β-defensins forms the 
disulfide linkages between Cys1–Cys5, Cys2–Cys4, and Cys3–Cys6. The θ-defensins are a 
class of circularly structured defensins with a cysteine spacing pattern of Cys1–Cys6, 
Cys2–Cys5 and Cys3–Cys4.  
 
The evolutionary relationships of defensins across plant, invertebrate and mammals 
are poorly understood, but highly conserved sequences, structures, and functions 
suggested that all defensins are evolutionarily related [24]. Especially in vertebrates, the 
defensin gene clusters on chromosomes are adjacent to each other, suggesting that all 
defensins are likely to arise from a common ancestor [25]. Hughes provided some 
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evidence indicating that vertebrate β-defensins are more like insect defensins rather than 
to vertebrate α-defensins [26]. Recent phylogenetic analyses from our research group 
revealed that α-defensins in glires and primates appeared after the divergence of 
mammalian species by a rapid duplication and positive selection [27], while θ-defensins 
are originated from α-defensins following the divergence of primates from other 
mammals [28].  
 
β-defensins are the most ubiquitous defensins in vertebrate animals with a wide 
expression pattern including mucosal epithelial cells and phagocytes, while α-defensins 
are produced by leukocytes and Paneth cells of small intestine in the human, rhesus 
macaque, rabbit, guinea pig, mouse, and rat [27]. Till now, only three θ-defensins have 
been discovered in leukocytes [29] and bone marrow [30] of rhesus monkeys. Although 
the human has several θ-defensin genes, but no θ-defensin peptides are produced due to 
the presence of a premature stop codon in the upstream sequence that prevents translation 
[28]. Mature θ-defensin peptides contain only 18 amino acids and are cyclized by two α-
defensin-like 9-amino acid sequences [31]. Generally defensins are stored as inactive 
precursors in cells. In response to microbial infections, active mature defensins will be 
released following proteolytic processing and target microbes locally [31]. All defensin 
precursors consist of a hydrophobic signal sequence, a pro-sequence, and a mature 
defensin peptide containing six-cysteine motif at the C-terminus [19].  To be biologically 
active, β-defensins need to be processed from the precursor by proteolytic enzymes, 
although enzymes for cleavage are yet to be identified. Recently, the processing enzymes 
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to release active α-defensin peptides, such as metalloproteinase Matrilysin (MMP-7) in 
mice [32] and trypsin in human [33], have been identified.  
  
Cathelicidins are a family of highly diverse antimicrobial peptides that share a 
common ancestor [34], and they have been found in fish [35, 36], birds [37] and 
mammals [38-44]. The first member of the cathelicidin family was isolated in early 1990s 
from porcine neutrophils [34]. Similar to defensins, cathelicidins are also stored as 
inactive precursors in cells. All cathelicidin precursors share highly conserved pre- and 
pro-sequences (“cathelin”) at the N-terminus, followed by diversified, cationic mature 
sequences at the C-terminus [8, 45, 46] (Figure 2). Generally, cathelicidin genes contain 
four exons and three introns [47]. The first three exons encode the pre- and pro-sequences, 
whereas the fourth exon encodes the mature peptide sequence [47]. The presequences 
range from 29 ~ 30 amino acids that act as signal peptides for secretion. The length of the 
“cathelin” domain is around 94 ~ 114 amino acids that contain four invariant cysteines 
forming two disulfide bridges [48]. The highly diverse C-terminal mature peptides are 
around 12 ~ 100 amino acids [8].  
 
Cathelicidins are mainly present in the granules of phagocytes, and also has been 
found in mucosal epithelial cells and keratinocytes as well [8, 45, 46]. The biologically 
active mature peptides are processed by proteolytic enzymes and released upon infections. 
Studies with bovine [49] and pig [50] cathelicidins indicated that elastase is the enzyme 
responsible for cleaving the pro-sequence and releasing the mature peptides to exert 
antimicrobial activity. The highly conserved “cathelin” domain of cathelicidins is 
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negatively charged and its biological function is still not clear. Recently, the “cathelin” 
domain of human cathelicidin precursor LL-37/hCAP-18 was found to kill bacterial 
strains that are resistant to mature peptide, suggesting a complementary antibacterial 
activity of the “cathelin” domain with mature peptides [51].  
 
2.3    Antimicrobial activity 
 
Antimicrobial peptides are so named because of their broad-spectrum antimicrobial 
activities [7, 16]. In addition to killing Gram-negative and Gram-positive bacteria [52, 
53], antimicrobial peptides are active against enveloped viruses [54, 55], fungi [56-58], 
parasite [53, 59, 60], and even cancer cells [61, 62]. In general, antimicrobial peptides kill 
most bacteria in micromolar concentrations, including antibiotic-resistant strains. For 
example, a sheep cathelicidin, SMAP-29, kills Pseudomonas aeruginosa and a 
methicilin-resistant strain of Staphylococcus aureus with a minimum inhibitory 
concentration (MIC) of 0.25 µM and 1 µM, respectively [8]. The antibiotic-resistance 
mechanisms that limited the use of conventional antibiotics don’t affect antimicrobial 
peptides due to their non-specific mode of action. But they are not perfect for all bacterial 
strains. For instance, the MICs of SMAP-29 and a cattle cathelicidin BMAP-29 against 
Burkholderia cepacia are ≥ 32 µM [8]. Melittin had minimal effect on several strains of 
Pseudomonas and Serratia [63]. 
 
Rapid bactericidal action is one of the essential features of an effective therapeutic 
agent because bacteria can double every 20-30 min under appropriate conditions. A 
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number of antimicrobial peptides have been reported to kill microbes quickly within 
several minutes in vitro. At the concentration of 0.06 µg/ml, Factor C protein isolated 
from the horseshoe crab, Carcinoscorpius rotundicauda, achieved 90% reduction in 
viable counts against Pseudomonas aeruginosa within 7 min [64]. Similarly, pig 
cathelicidin, Protegrin-1, reduced the number of viable methicillin-resistant S. aureus 
(MRSA) or P. aeruginosa up to three log units in less than 15 minutes [65].  
 
However, factors like salt and serum are known to alter the intensity of the microbial 
killing activity of antimicrobial peptides [66]. Kandasamy et al. [67] studied the effect of 
salt on the interactions of frog antimicrobial peptide, magainin, with zwitterionic lipid 
bilayers, indicating that the binding of peptide to the lipids is stronger at lower 
concentrations of salt. The peptide interacted quickly with the membrane and caused lipid 
disorder, but this effect was diminished as the salt concentration increased [67]. 
Nevertheless, a few peptides displayed salt-independent antimicrobial activities. For 
example, a sheep cathelicidin, SMAP-29, was more effective against bacteria in the 
presence of 100 mM NaCl [68], and LL-37/hCAP18 retained its killing efficacy against 
vancomycin-resistant enterococci in both low- and high- salt media [69, 70]. Human β-
defensin 3 (hBD-3) exerted potent antimicrobial activity at physiologic concentrations of 
NaCl (150 mM), but in vitro assay showed that the activity was inhibited in the presence 
of 20% human serum [71]. It is likely that the proteases or certain proteins in the serum 
reduced the availability of the peptide to bacteria, and the high ionic strength or salt 
properties could also contribute to its inhibition [72].  
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Some antimicrobial peptides showed synergy with conventional antibiotics and other 
antimicrobial peptides in killing bacteria. For example, protegrin-1 is synergistic with 
cathelicidins from bovine (indolicidin) and human (LL-37) in killing antibiotic-resistant 
bacteria including P. aeruginosa and methicilin-resistant S. aureus efficiently [73]. 
Citropin 1.1, an antimicrobial peptide derived from the Australian tree frog, Litoria 
citropa, demonstrated synergy with conventional antibiotics like clarithromycin, 
doxycycline, and rifampicin against rifampicin-resistant Rhodococcus equi [74].  
 
In addition to killing bacteria, many antimicrobial peptides exhibit direct antifungal 
and antiparasitic activities as well. For example, plant defensins, α-, β- and γ-thionins are 
selective against fungi [6, 75]. Insect defensins, heliomicin [76] and gallerimycin [77], 
also display similar antifungal activities [78]. In addition, the human cathelicidin LL-37 
[79], sheep cathelicidin SMAP-29 [56], and mouse cathelicidin mCRAMP [79] are 
effective against C. albicans. Gomesin, purified from the hemocytes of the tarantula 
spider Acanthoscurria gomesiana, affected the viability of the parasite Leishmania 
amazonensis at 2.5 µM [80]. Insect antimicrobial peptide, cecropin A, has a lethal effect 
on the parasite, Trypanosoma cruzi, at 150–500 µM [81].  
 
Moreover, certain antimicrobial peptides have antiviral activities. Horseshoe crab 
antimicrobial peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), is of great interest because 
it specifically block T cell-line HIV-1 infection by recognizing and binding to a 
chemokine receptor (CXCR4) [82, 83]. Lactoferricin, an iron-binding protein that is 
present in milk, has been shown to effectively block the entry of herpes simplex virus 
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(HSV) into the host cells [84]. Human α-defensins 1-3 (HNPs 1-3) and human α -
defensin 5 (HD-5) are potent against both cutaneous and mucosal papillomavirus types, 
which are the primary cause of cervical cancer [85].  
 
2.4    Mechanisms of action 
 
A common mechanism by which antimicrobial peptides kill bacteria appears to be 
mediated through physical interactions with negatively-charged bacterial membranes 
followed by membrane disruption [86, 87]. The interaction between antimicrobial 
peptides and bacterial membrane is regarded as the first and essential step for the 
antibacterial activity. Generally, antimicrobial peptides kill bacteria more efficiently than 
eukaryotic host cells because of the differences between prokaryotic and eukaryotic 
membrane characteristics [9]. Bacteria have highly negatively charged membranes due to 
the presence of a high percentage of negatively charged phospholipid, anionic LPS, 
lipoteichoic acid, and peptidoglycan. In contrast, eukaryotic membranes have much lower 
content of anionic lipids and high content of cholesterol [9]. In the case of Gram-negative 
bacteria, anionic LPS is stabilized by divalent cations such as Mg2+ and Ca2+. 
Electrostatic interactions of cationic peptides with LPS can displace divalent cations 
leading to a local disturbance in the outer membrane [88]. Peptides then integrate into the 
outer membrane and cause membrane thinning as observed by X-ray diffraction [88].  
 
However, the outer membrane interaction with peptides is believed not sufficient for 
cell death [89]. Three major models have been proposed to account for membrane 
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disruption [88, 90, 91]. The “barrel-stave” model suggests that peptide monomers bind to 
cytoplasmic membrane and insert into membrane by forming a pore. The pore size is 
increased by progressively recruiting more peptide monomers [87]. In the “toroidal pore” 
model, pores form differently due to the curvature strain produced by lipids bending 
when peptides accumulate on the surface of membrane [92]. The third “carpet” model 
suggests that peptides lay on the surface of cytoplasmic membrane and lead to disruption 
of membrane until the concentration of peptides reaches the threshold [87]. The physico-
chemical properties of peptides and lipids dictate the mode of action [93]. Membrane 
damages caused by antimicrobial peptides are believed to be one of the major reasons 
responsible for microbial death.  
 
Besides bacterial membranes, accumulating evidence has shown that antimicrobial 
peptides can attack intracellular targets after peptides translocate across the cytoplasmic 
membrane. Insect antimicrobial peptides such as pyrrhocoricin, apidaecin, and drosocin 
are capable of inhibiting the activity of heat shock protein, DnaK, leading to 
accumulation of misfolded protein within the cytoplasm causing cell death [94]. Buforin 
II, isolated from the stomach of Asian toad, can bind to DNA and RNA of cells and 
inhibit cellular functions [95]. Lactoferricin B, a cationic peptide derived from bovine 
lactoferrin, when applied to E. coli at concentrations insufficient to kill bacterial cells, 
can induce an initial increase in protein and RNA synthesis and a decrease in DNA 
synthesis [96].  
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The phenomenon that antimicrobial peptides have multiple intracellular targets is 
generally explained by a “multi-hit” model proposed by Hancock’s group [9, 95]. This 
model shows that, in addition to the physical disruption of the bacterial membrane, 
antimicrobial peptides can translocate across the membrane and bind to intracellular 
anionic molecules including DNA, RNA, and certain proteins, which collectively results 
in the inhibition of macromolecular synthesis.  
 
The unique mechanism of action that differs from that of conventional antibiotics 
makes cationic antimicrobial peptides attractive to be developed as therapeutic agents. 
Because the peptides interact with membranes via electrostatic interactions, development 
of resistance is highly unlikely due to extreme difficulty in changing its membrane 
composition through mutations. 
 
The mechanism of antiviral activity of antimicrobial peptides is not very clear. It is 
generally believed that peptides have a dual role in antiviral activity [97].  By a similar 
antibacterial mechanism, peptides can interact with viral envelopes and directly inactivate 
viral particles. In addition, peptides inhibit viral replication by interacting indirectly with 
host cells through the binding of cell-surface glycoproteins and/or interfering with cell-
signaling pathways. 
 
2.5    Roles in innate immunity and other biological processes 
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In addition to their direct antimicrobial activity, growing evidence has suggested that 
antimicrobial peptides play an important modulatory role in response to inflammation 
and infection [9, 98, 99]. For example, Human α-defensin -1 (HNP-1) was found to be 
capable of blocking NADPH oxidase activation in vitro and may act in vivo by inhibiting 
excessive activation of the oxidase thus preventing overproduction of oxygen radicals 
[100]. Human neutrophil peptides HNP-(1-3) are able to bind to endothelial cells and 
fibrin and subsequently inhibit tissue-type plasminogen activator (tPA) and plasminogen-
mediated fibrinolysis thereby limiting the spread of infection [101].  
 
A number of antimicrobial peptides display a direct chemotactic activity for 
neutrophils, monocytes, mast cells, immature dendritic cells, and T helper cells to the 
sites of infection. The peptides isolated from skin secretions of the North American dusky 
gopher frog, Rana sevosa, could attract neutrophils to the sites of infection and help to 
destroy bacteria [102].  
 
Additionally, antimicrobial peptides can induce the production and release of 
chemokines and/or cytokines. Human neutrophil peptides HNP-(1-3) have been shown to 
significantly increase the IL-8 levels in airway epithelial cells [103], and defensin-induced 
IL-8 production enhanced the release of secretory leukocyte proteinase inhibitor (SLPI), 
which functions as an inhibitor of neutrophil elastase in addition to direct antibacterial 
and antifungal activities [104]. Similarly, human cathelicidin LL-37 induces IL-8, IL-18 
and IL-20 production by human keratinocytes through activation of the MAP kinase 
pathway, and synergizes with HNP1-4 in increasing IL-18 production [105]. 
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Paradoxically, antimicrobial peptides can also protect the host by suppressing the 
excessive inflammatory responses. Cationic peptides are able to bind anionic LPS and 
further neutralize LPS-induced production of cytokines/chemokines such as IL-1β, TNFα, 
and IL-6 [106, 107]. The immuno-modulating effects of antimicrobial peptides probably 
involve multiple mechanisms, but remain elusive [98].  
 
Some antimicrobial peptides have been reported to promote wound healing. The 
presence of pig cathelicidin PR-39 in wound fluid induces mesenchymal cells to express 
specific cell surface syndecan-1 and -4, which are able to bind heparin-binding growth 
factors such as fibroblast growth factor 2, heparin-binding epidermal growth factor-like 
growth factor and platelet-derive growth factor, leading to cell proliferation and 
migration [108]. The binding of syndecan-1 to fibronectin, tenascin and fibrillar 
collagens would contribute to wound repair [108]. Human cathelicidin LL-37 has been 
reported to associate with the wound repair process by stimulating keratinocyte 
proliferation and inducing angiogenesis [109, 110]. 
 
Besides a role in immunity and host defense, antimicrobial peptides are involved in 
other biological processes as well. For example, rat peptide Bin1b, an epididymis-specific 
β-defensin, is capable of binding sperm and initiating maturation process by inducing the 
uptake of Ca2+ and progressive mobility of immature sperm [111]. In fact, most β-
defensins have been found to be expressed preferentially in epididymis [111-113].  
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2.6    Therapeutic potential 
 
Although a few of antimicrobial peptides display potent antimicrobial activity and 
immunomodulatory effects, they also exhibit considerable cytotoxicity toward host cells. 
For example, melittin is a potent antimicrobial peptide found in European honey bee 
venom, but with significant cytotoxicity toward human intestinal epithelial cells, HT29 
and Caco-2 [114]. Nevertheless, the concentrations of antimicrobial peptides that are 
required to exert a noticeable cytolytic effect are often much higher (10-1000 times) than 
microbicidal concentrations [8], indicating their therapeutic potential.  
 
Structure-based rational mutagenesis of natural peptides is being employed to reduce 
cytotoxicity while maintaining or increasing the antimicrobial activity. Several physico-
chemical properties like amphiphilicity, helicity, flexibility and charges are among the 
most critical factors that affect their biological activities and can be manipulated for a 
beneficial outcome [9]. For example, tritrpticin, a cathelicidin deduced from porcine 
myeloid, has a broad spectrum of antimicrobial activity with relatively strong hemolytic 
activity [115]. A perfect symmetric analogue of tritrpticin with C-terminal amidation, 
was shown to reduce hemolysis and permeabilization of the zwitterionic 
phosphatidylcholine membrane with 2~8 fold improvement in antimicrobial activity 
[116]. Novispirin G10, an antimicrobial peptide analogue derived from sheep cathelicidin 
SMAP-29, exhibited enhanced specificity and antimicrobial activity toward antibiotic-
resistant Pseudomonas spp following rational changes of the native peptide [117].  
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Taken together, the characteristics of antimicrobial peptides including the broad-
spectrum microbicidal activity, rapid action, potential low levels of resistance and 
immunomodulatory effects make them good candidates for therapeutic agents [118]. 
Antimicrobial peptides are being developed as novel therapeutics with several in various 
stages of clinical trials. For example, Pexiganan (MSI-78), a peptide derived from frog 
magainin 2, is the first cationic peptide to be developed as a commercial antibiotic to treat 
infected diabetic foot ulcers [9].  Omigana, an indolicidin-like peptide, is under the Phase 
III trial for prevention or treatment of catheter-associated infections [119]. Table 1 is a 
list of antimicrobial peptides that are being developed as therapeutic agents [9, 118, 120]. 
Detailed structural and functional studies about additional novel antimicrobial peptides 
will facilitate the development of new anti-infective therapeutic agents, particularly 
against antibiotic-resistant pathogens [121].  
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Table 1. A list of cationic antimicrobial peptide drugs that are being developed for 
various disease treatments [9, 118, 120] 
Compound Company Testing status Disease drug designed to treat 
Pexiganan Magainin Pharmaceeticals Phase III completed Infection of diabetic foot ulcers 
Iseganan IntraBiotics Corportation Phase III halted 
prematurely 
Ventilator-associated pneumonia 
Omiganan 
(MBI 226) 
 
Migenix (formerly 
Micrologix) 
Phase III completed Infections at site of in-dwelling 
catheter insertion 
MBI 594AN 
 
Microbiologx  Phase II  Acute acne 
IMXC001 
 
Inimex Pharmaceuticals Preclinical Sepsis 
P113 P113D Demegen Phase II completed Oral candidiasis in HIV patients 
RBPI21 
 
Xoma Ltd. Phase III completed Severe bacterial meningitis 
XMP.629 
 
Xoma Ltd. Phase III halted Acute acne 
Mycoprex 
(XMP366) 
 
Xoma Ltd. Preclinical 
development 
Systemic fungal infections 
Histatine 
variants 
 
Periondotix Phase II 
Phase I 
Gingivitis and mouth infections  
oral candidiasis 
Heliomocin 
variants 
(ETD151) 
Entomed SA Preclinical 
development 
Systemic deep and invasive fungal 
infections, immunocompromised 
patients 
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Figure 1.  Representative peptide sequences of three classes of mammalian defensins. 
Also shown are the net positive charges (in parenthesis) and intra-molecular disulfide 
bridges of each peptide.  Abbreviations: HNP-4, human neutrophil α-defensin-4; hBD-3, 
human β-defensin-3; HTD-1, human θ-defensin-1. 
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Figure 2. Schematic representation of a cathelicidin precursor. Cathelicidins consist 
of a highly conserved preprosequence followed by a diverse mature peptide that 
possesses antimicrobial activity. Four cysteines within the pro-sequence form two 
intracellular disulfide bridges. 
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3.1    Abstract 
 
Background: Defensins comprise a large family of cationic antimicrobial peptides 
that are characterized by the presence of a conserved cysteine-rich defensin motif. Based 
on the spacing pattern of cysteines, these defensins are broadly divided into five groups, 
namely plant, invertebrate, α-, β-, and θ-defensins, with the last three groups being 
mostly found in mammalian species. However, the evolutionary relationships among 
these five groups of defensins remain controversial.  
Results: Following a comprehensive screen, here we report that the chicken genome 
encodes a total of 13 different β-defensins but with no other groups of defensins being 
discovered.  These chicken β-defensin genes, designated as Gallinacin 1-13, are clustered 
densely within a 86-Kb distance on the chromosome 3q3.5-q3.7. The deduced peptides 
vary from 63 to 104 amino acid residues in length sharing the characteristic defensin 
motif. Based on the tissue expression pattern, 13 β-defensin genes can be divided into 
two subgroups with Gallinacin 1-7 being predominantly expressed in bone marrow and 
the respiratory tract and the remaining genes being restricted to liver and the urogenital 
tract. Comparative analysis of the defensin clusters among chicken, mouse, and human 
suggested that vertebrate defensins have evolved from a single β-defensin-like gene, 
which has undergone rapid duplication, diversification, and translocation in various 
vertebrate lineages during evolution. 
Conclusions: We conclude that the chicken genome encodes only β-defensin 
sequences and that all mammalian defensins are evolved from a common β-defensin-like 
ancestor. The α-defensins arose from β-defensins by gene duplication, which may have 
occurred after the divergence of mammals from other vertebrates, and θ-defensins have 
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arisen from α-defensins specific to the primate lineage. Further analysis of these 
defensins in different vertebrate lineages will shed light on the mechanisms of host 
defense and evolution of innate immunity.  
 
3.2    Background 
 
Defensins constitute a large family of small, cysteine-rich, cationic peptides that are 
capable of killing a broad spectrum of pathogens, including various bacteria, fungi, and 
certain enveloped viruses [1-5]. These peptides play a critical role in host defense and 
disease resistance by protecting the hosts against infections. Transgenic mice expressing 
human enteric defensin HD5 are fully protected against the doses of Salmonella 
typhimurium that are otherwise lethal to the wide-type mice [6]. Conversely, mice 
deficient in the matrilysin gene, which is responsible for activating enteric defensins, 
become more susceptible to oral infection with S. typhimurium [7].  
 
Defensins have been identified in species ranging from plants, insects to animals and 
humans [1-5]. Characterized by the presence of 6-8 cysteine residues in relatively defined 
positions, all defensins are structurally related in that they form 3-4 intramolecular 
disulfide bonds and 2-3 antiparallel β-sheets with or without an α-helix. Based on the 
spacing pattern of cysteines, these peptides are broadly divided into five groups; namely 
plant, invertebrate, α-, β-, and θ-defensins [1-5]. Alignment of all known defensin 
sequences revealed the consensus defensin motif of each group as follows: plant defensin: 
C-X8-11-C-X3-5-C-X3-C-X9-12-C-X4-11-C-X1-C-X3-C; invertebrate defensin: C-X5-16-C-X3-
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C-X9-10-C-X4-7-C-X1-C; α-defensin: C-X1-C-X3-4-C-X9-C-X6-10-C-C; and β-defensin: C-
X4-8-C-X3-5-C-X9-13-C-X4-7-C-C. The α- and β-defensins are unique to vertebrate animals 
with α-defensins only being found in rodents and primates, while β-defensins are present 
in all mammalian species investigated [1-3]. On the other hand, θ-defensins have only 
been found in certain primates as a result of posttranslational ligation of two α-defensin-
like sequences [8-10]. A pseudogene for θ-defensin is also present in humans [11].  
 
Analysis of human and mouse genomes indicated that β-defensins form 4-5 distinct 
clusters on different chromosomes with each cluster consisting of multiple defensin genes 
[12]. Interestingly, the single mammalian α-defensin locus is located on a β-defensin 
cluster with θ-defensins residing in the center of α-defensins [12]. Studies with 
mammalian defensins suggested a rapid duplication followed by positive selection and 
diversification within each group [13-18]. However, the evolutionary relationships 
among three groups of mammalian defensins and among plant, invertebrate, and 
mammalian defensins remain controversial. Similarity in spatial structure and biological 
functions favors the notion that all mammalian defensins are evolutionarily related [19], 
although a phylogenetic analysis suggested a closer relationship between β- and insect 
defensins than between α- and β-defensins [16]. 
 
Existence of a large number of expressed sequence tag (EST) sequences and recent 
completion of chicken genome sequencing at a 6.6× coverage [20] provided a timely 
opportunity to discover a complete repertoire of defensin-related sequences in birds for 
studying the evolutionary relationship between invertebrate and mammalian defensins. 
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Here we report identification of a single β-defensin cluster that is composed of 13 genes 
located on the chicken chromosome 3q3.5-q3.7. Evolutionary and comparative analyses 
of these chicken β-defensins with mammalian homologues strongly suggested that all 
mammalian defensins have evolved from a common β-defensin-like ancestor, which has 
undergone rapid duplication, positive diversifying selection, and chromosomal 
translocations, thereby giving rising to multiple gene clusters on different chromosomal 
regions. 
 
3.3    Results and discussion  
 
Discovery of novel chicken defensins 
To identify novel defensin genes in the chicken, all five groups of known defensin-
like peptide sequences from plants, invertebrates, and vertebrates were first queried 
individually against the translated chicken nonredundant (NR), EST, high throughput 
genomic sequence (HTGS), and whole-genome shortgun sequence (WGS) databases in 
the GenBank by using the TBLASTN program[21]. All potential hits were then examined 
manually for the presence of the characteristic cysteine motifs. For every novel defensin 
identified, additional iterative BLAST searches were performed until no more novel 
sequences could be found. In addition to three known chicken β-defensins (Gal 1-3) [22, 
23], nine novel putative sequences, namely Gal 4-12, have been found in the EST 
database with at least two hits for each, and such sequences have also been confirmed in 
genomic sequences (Table 1). Because of the fact that mammalian defensins tend to form 
clusters [12, 14, 15, 18], all chicken HTGS and WGS sequences containing defensin 
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sequences were also retrieved from GenBank, translated into six open reading frames, 
and manually curated. As a result, an additional putative β-defensin, Gal13, was 
identified in several genomic clones (Table 1). The open reading frame of Gal13 was 
predicted by GENSCAN [24] and confirmed by directly sequencing of RT-PCR product 
amplified from chicken kidney.  
 
No other sequence containing β-defensin-like six-cysteine motif has been found in 
NR, EST or genomic databases, suggesting that 13 Gal genes constitute the entire 
repertoire of the β-defensin family encoded in the chicken genome. Although it is highly 
unlikely, we could not rule out the possibility that additional defensin-related genes with 
distant homology might be uncovered in the chicken by different computational search 
methods such as the use of Hidden Markov models [12, 15]. It is noted that none of other 
groups of defensins have been discovered in the chicken, indicating that plant, 
invertebrate, α-, and θ-defensins are absent in the chicken lineage. 
 
Similar to Gal 1-3, 10 novel β-defensins, deduced from either EST or genomic 
sequences, vary from 63 to 104 amino acid residues in length. Alignment of these 
peptides revealed a conservation of the signal sequence at the N-terminus and the 
characteristic six-cysteine defensin motif at the C-terminus (Figure 1). Consistent with 
the fact that all β-defensins are a group of secreted molecules in response to infections, 
the signal sequences of all chicken defensins are hydrophobic and rich in leucines. In 
addition, the mature C-terminal sequences are all positively charged due to the presence 
of excess arginines and lysines. Interestingly, Gal11 contains two tandem, but highly 
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divergent, copies of the six-cysteine motif at the C-terminus, and is the only defensin 
having such sequences. Functional significance for existence of such two defensin motifs 
remains to be studied.  
 
Evolutionary analysis of vertebrate β-defensins 
Phylogenetic analysis of vertebrate β-defensins showed that chicken defensins 
clustered with various different groups of mammalian β-defensins (Figure 2). However, 
the bootstrap support for these patterns was very weak (less than 50% in all cases). The 
clustering of certain chicken β-defensins with mammalian homologues suggests that 
major subfamilies of β-defensins arose before the last common ancestor of birds and 
mammals, estimated to have occurred about 310 million years ago [25]. This in turn 
implies that some duplication of β-defensin genes must have taken place before the 
divergence of birds and mammals. The apparent lack of α-defensins in the chicken and 
other non-mammalian species (G. Zhang, unpublished data) suggests that α-defensins 
may have evolved after mammals diverged from other vertebrates. 
 
Comparison of the numbers of synonymous and nonsynonymous nucleotide 
substitutions provides a powerful test of the hypothesis that positive Darwinian selection 
has acted to favor changes at the amino acid level [26]. This approach has previously 
been applied to both α- and β-defensins of mammals and has revealed positive selection 
acting on the mature defensin but not on other regions of the gene [16, 17]. In the 
comparison of the chicken β-defensin sequences, synonymous sites were saturated with 
changes or nearly so, making it impossible to test the hypothesis of positive selection in 
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every case. In pairwise comparisons among all sequences, mean pS in the propeptide 
region was 0.551 ± 0.036 (S.E.), while mean pN was 0.369 ± 0.040. In the mature 
defensin region, mean pS was 0.673 ± 0.027, while mean pN was 0.534 ± 0.051. Mean pN 
in the mature defensin was significantly greater than that in the propeptide (z-test; P < 
0.05), indicating lesser functional constraint on the amino acid sequence of the former. 
The high mean pS shows that chicken β-defensin genes have not duplicated recently, 
unlike β-defensin genes of the bovine [16].  In the comparison between the most closely 
related pair of sequences (Gal6 and Gal7), mean pS in the mature defensin was 0.221 ± 
0.082, while mean pN was 0.331 ± 0.076. While these values are not significantly 
different at the 5% level, the fact that pN was higher than pS suggested that positive 
selection may have acted to diversify the mature defensin region between these two genes. 
 
Genomic organization and chromosomal localization of the chicken β-defensin gene 
cluster 
Searching through HTGS database led to identification of two overlapping bacterial 
artificial chromosome (BAC) sequences, TAM31-54I5 (accession no. AC110874) and 
CH261-162O9 (accession no. AC146292), both of which were sequenced and deposited 
earlier by one of us (J.F. Chen). Alignment of these two sequences allowed to re-order 
three DNA fragments in AC110874 and to construct a continuous, gap-free genomic 
contig that includes 11 Gal genes except for Gal4 and Gal5. Later search of chicken 
WGS sequences released on February 29, 2004 confirmed the order of the genomic 
contig that we assembled and also revealed the locations of two remaining genes, Gal4 
and Gal5, both of which reside on a WGS (accession no. AADN01058096) that overlaps 
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with AC110874 (Figure 3). The position and orientation of each Gal gene were obtained 
by comparing its cDNA with the assembled DNA sequence. As shown in Figure 3, all 13 
Gal genes were clustered densely within a distance of 86.0 Kb on the genome. It was also 
confirmed by aligning such a contig with the chicken genome assembly, in which 13 Gal 
genes are located on six WGS contigs (Table 1) of chromosome 3 that are only ~3.3 Mb 
from the distal end. Consistent with this, the Gal gene cluster was physically mapped to 
the tip of chicken chromosome 3 at the region of q3.5-q3.7 by fluorescence in situ 
hybridization (FISH) using the TAM31-54I5 BAC DNA as probe (Figure 4). 
 
Comparing the cDNA with genomic sequences also revealed the structure of each Gal 
gene. Unlike most mammalian β-defensin genes, which primarily consist of two exons 
and one intron, the Gal genes were found to be composed of four short exons separated 
by three introns with variable lengths ranging from 117 bp to 3,322 bp (Table 1). Gal12 
is an exception, in which the last two exons have been fused together. While the first 
exon of the Gal genes encodes 5’-untranslated region (UTR) and the majority of the last 
exon encodes 3’-UTR as well as a few C-terminal amino acids, two internal exons 
resemble mammalian β-defensin genes in that one exon encodes the signal and pro-
sequence and the other encodes the mature sequence with six-cysteine motif [19, 27-29]. 
Apparently, the first two and the last two exons of the Gal genes have joined together 
during the evolution as a result of exon shuffling, which occurred in many other 
evolutionarily conserved gene families [30], including invertebrate defensins [5]. The 
fusion of defensin exons in mammals is presumably adaptive because it allows a faster 
mobilization of such host defense molecules to better cope with invading microbes.  
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Tissue expression patterns of chicken β-defensins 
It has been shown that Gal1 and Gal2 are expressed in bone marrow and lung, while 
Gal3 is more preferentially expressed in bone marrow, tongue, trachea, and bursa of 
Fabricius [23]. To study the tissue expression patterns of novel Gal genes that we 
identified, RT-PCR was performed with a panel of 32 different chicken tissues. Similar to 
Gal 1-3, Gal 4-7 are highly restricted to bone marrow cells with Gal5 also expressed in 
tongue, trachea, lung, and brain at lower levels (Figure 5). By contrast, the six remaining 
genes, Gal 8-13, were not found in bone marrow, but instead in liver, kidney, testicle, 
ovary, and male and female reproductive tracts (Figure 5). These results clearly suggested 
that all chicken β-defensin genes can be divided into two subgroups.  Seven genes (Gal 1-
7) are predominantly expressed in bone marrow and the respiratory tract, whereas the 
other six genes (Gal 8-13) are more restricted to liver and the urogenital tract. However, 
the functional significance and transcriptional regulatory mechanisms of these genes 
during inflammation and infection remain to be investigated. 
 
Comparative analysis of chicken and mammalian β-defensin gene clusters 
To study the origin and evolution of mammalian defensins, a comparative analysis of 
β-defensin gene clusters in the chicken, mouse, and human was performed by employing 
additional, more phylogenetically conserved gene markers surrounding the defensin 
clusters. As shown in Figure 6, two genes, CTSB (Cathepsin B, accession no. NP_680093) 
and a human EST sequence (accession no. BE072524) immediately located centromeric 
to chicken defensins, were also found to be conserved in the defensin gene clusters on 
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human chromosome 8p22 and mouse chromosome 14C3. Similarly, another gene, 
HARL2754 (accession no. XP_372011) that is 6-Kb telemetric to Gal4 is also conserved 
in another defensin cluster in human (8p23) or mouse (8A1.3) (Figure 6).  
 
These results strongly suggested that all vertebrate β-defensins are evolved from a 
single gene. This conclusion is further supported by the fact that there are three highly 
similar β-defensin-like sequences present in the largely finished zebrafish genome (G. 
Zhang, unpublished data). In addition, a group of homologous β-defensin-like sequences, 
namely crotamine and myotoxins, have been found in several Crotalus snakes [31], 
which are presumably derived from a single ancestral gene. The appearance of multiple 
β-defensin gene clusters on different chromosomal regions in mammalian species [12] is 
apparently a result of rapid gene duplication, positive diversifying selection, and 
chromosomal translocation following divergence of mammals from other vertebrate 
lineages.  
 
In addition to the structural conservation between β-defensin-like sequences in the 
rattlesnake and mammals [32], a growing body of evidence suggests that their functions 
appear to be largely conserved in that both are capable of interacting negatively-charged 
lipid membranes followed by formation of ion channels or pores [32-34].  It is 
noteworthy that the conservation of Cathepsin B (CTSB) adjacent to β-defensins is 
perhaps not surprising, given the recent finding that cathepsins are involved in the 
cleavage and inactivation of β-defensins [35]. 
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3.4    Conclusions  
 
We have showed that chicken genome encodes a total of 13 different β-defensin 
genes clustered densely within a 86-Kb distance on the chromosome 3q3.5-q3.7, but with 
no α-defensin genes. These peptides exhibit homology to different subgroups of 
mammalian β-defensins, consistent with the hypothesis that α-defensins and β-defensins 
arose by gene duplication after the divergence of birds and mammals. The θ-defensins are 
specific to primates; and thus appear to have arisen from α-defensins by gene duplication 
specific to the primate lineage. Apparently, the evolution of defensins is rapid and driven 
by duplication and positive diversifying selection. Collectively, this study represents the 
first large-scale detailed investigation of defensins in non-mammalian vertebrates. There 
is no doubt that further analysis of these defensin genes will lead to a better 
understanding of host defense mechanisms and evolution of innate immunity. 
 
3.5    Methods 
 
Computational search for novel chicken defensins 
To identify novel defensins in the chicken, all known cysteine-containing defensin-
like peptide sequences discovered in plants, invertebrates, birds, and mammals were 
individually queried against the translated chicken NR, EST, HTGS, and WGS databases 
in the GenBank by using the TBLASTN program [21] with default settings on the NCBI 
web site [36]. All potential hits were then examined for the presence of the characteristic 
defensin motif. For every novel defensin identified, additional iterative BLAST searches 
were performed until no more novel sequences could be revealed. Because mammalian 
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defensins tend to form clusters [12, 14, 15, 18], all chicken genomic sequences 
containing defensin sequences were also retrieved from the GenBank and translated into 
six open reading frames and curated manually for the presence of the defensin motif in 
order to discover potential sequences with distant homology.  
 
Alignment and phylogenetic analysis of chicken β-defensins 
Multiple sequence alignment was constructed by using the ClustalW program 
(version 1.82) [37]. A phylogenetic tree of amino acid sequences of mature β-defensins 
was constructed by the neighbor-joining method [38]. So that a comparable data set 
would be used for all pairwise comparisons, any site at which the alignment postulated a 
gap in any sequence was excluded from the analysis. To maximize the number of sites 
available for analysis, certain sequences with large deletions were excluded from the 
analysis. Because the sequences were very short (25 aligned sites), no correction for 
multiple hits was applied. The reliability of clustering patterns within the tree was 
assessed by bootstrapping; 1000 bootstrap pseudo-samples were used. The proportion of 
synonymous nucleotide differences per synonymous site (pS) and the proportion of 
nonsynonymous nucleotide differences per nonsynonymous site (pN) were estimated by 
the method of Nei and Gojobori [26]. Again, no correction for multiple hits was applied 
because a small number of sites were examined. 
 
Assembly of the chicken β-defensin gene cluster 
To generate a continuous defensin gene cluster, the HTGS and WGS sequences 
containing the putative defensin genes were retrieved from the GenBank, aligned to 
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generate a longer contig, which was confirmed later by searching through the assembled 
chicken genome released on February 29, 2004, by using the BLAT program [39] under 
the UCSC Genome Browser web site [40]. The relative positions, orientations, and 
structural organizations of individual genes were determined by comparing its cDNA 
sequence to the continuous genomic contig that we assembled.   
 
Chromosome localization of the chicken β-defensin gene cluster 
Fluorescence in situ hybridization (FISH) was used for chromosomal assignment of 
the chicken β-defensin gene cluster by using the BAC clone TAM31-54I4 as probe, 
which harbors 11 Gal genes. Metaphase chromosome speads were prepared from 
mitogen-stimulated chicken splenocyte culture as we described [41, 42]. The BAC clone 
was labeled by nick translation with biotin 16-dUTP (Roche Diagnostics), hybridized to 
metaphase chromosome DNA, followed by detection with FITC-labeled avidin (Roche 
Diagnostics) and staining with propidium iodide to simultaneously induce the R-banding. 
 
RT-PCR analysis of the tissue expression patterns of chicken β-defensins 
Total RNA was extracted with Trizol (Invitrogen) from a total of 32 different tissues 
from healthy, 2-month-old chickens (see Figure 5). A total of 4 µg RNA from each tissue 
were reverse transcribed with random hexamers and Superscript II reverse transcriptase 
by using a first-strand cDNA synthesis kit (Invitrogen) according to the instructions. The 
subsequent PCR was carried out with 1/40 of the first-strand cDNA and gene-specific 
primers for each β-defensin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
described [28, 43]. Every pair of primers were designed to locate on different exons to 
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aid in distinguishing PCR products amplified from cDNA vs. genomic DNA (Table 2). 
The PCR program used was: 94oC denaturation for 2 min, followed by different cycles of 
94oC denaturation for 20 sec, 55oC annealing for 20 sec, and 72oC extension for 40 sec, 
followed by a final extension at 72oC for 5 min. The number of PCR cycle was 
optimized for each gene to ensure linear amplification (Table 2). A half of the PCR 
products were analyzed by electrophoresis on 1.2% agarose gels containing 0.5 µg/ml 
ethidium bromide. The specificity of each PCR product was confirmed by cloning of the 
PCR product into T/A cloning vector, followed by sequencing of the recombinant 
plasmid. 
 
3.6    Note added in proof  
 
Following submission of this manuscript, Lynn et al. reported independently 
discovery of seven novel chicken β-defensins in the chicken EST database by using 
homology search strategies [44]. Consistent with our conclusion, they also revealed 
occurrence of positive selection particularly in the mature region of chicken β-defensins 
following evolutionary analysis. Moreover, albeit the use of a different nomenclature, 
they confirmed that the expressions of Gal 4-7 are primarily in bone marrow, while other 
genes are more restricted to liver and the genitourinary tract. 
 
3.7    List of abbreviations     
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Abbreviations: Gal, Gallinacin; NR, nonredundant; EST, expressed sequence tag; 
HTGS, high throughput genomic sequence; WGS, whole-genome shortgun sequence; 
BAC, bacterial artificial chromosome; FISH, fluorescence in situ hybridization; UTR, 
untranslated region; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
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Figure 1. Multiple sequence alignment of chicken β-defensins: The intervening region 
between signal and mature peptide sequence is the short propiece. The conserved 
residues are shaded.  Also shown is the length of each peptide. Notice the six-cysteine 
defensin motif is highly conserved. The six cysteines in the second tandem copy of the 
defensin motif in Gal11 are boxed. 
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Figure 2. Phylogenetic relationship of 
vertebrate β-defensins: The tree was 
constructed by the neighbor-joining 
method and the reliability of each 
branch was assessed by using 1000 
bootstrap replications. Numbers on the 
branches indicate the percentage of 
1000 bootstrap samples supporting the 
branch. Only branches supported by a 
bootstrap value of at least 50% are 
indicated. Chicken β-defensins are 
highlighted in yellow. Abbreviations: 
BNBD, bovine neutrophil β-defensin; 
LAP, lingual antimicrobial peptide; 
EBD, enteric β-defensin; TAP, tracheal 
antimicrobial peptide; PBD, porcine β-
defensin; DEFB/Defb, β-defensin; Gal, 
Gallinacin; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase. 
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Figure 3. Genomic organization of the chicken β-defensin gene cluster: The 
horizontal lines at the bottom represent the three overlapping genomic clones that were 
used to assemble the continuous, gap-free contig. The position of each gene is 
represented by a solid vertical bar and the width of each bar is proportional to the size of 
each gene. The direction of transcription is indicated by the triangle above each gene. The 
genes with solid triangles are transcribed in the direction opposite to the ones with open 
triangles. Slanted lines refer to the sequences omitted. Note that the three fragments of 
AC110874 sequence have been re-ordered and the gaps have been filled following 
alignment with AC146292. 
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Figure 4. Chromosomal localization of the chicken β-defensin gene cluster by 
fluorescence in situ hybridization: The BAC clone TAM31-54I4, which harbors 11 Gal 
genes, was mapped to chicken chromosome 3q3.5-q3.7. Arrows indicate the 
hybridization signals.  
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Figure 5. Tissue expression patterns of 10 novel chicken β-defensins by RT-PCR: 
See Materials and Methods for details. The number of PCR cycles was optimized for 
each gene, and the specificity of each PCR product was confirmed by sequencing. The 
house-keeping gene, GAPDH, was used for normalization of the template input.  
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Figure 6. Comparative analysis of defensin clusters among the chicken, mouse, and 
human: The gene clusters were drawn proportionally according to their sizes. Each 
vertical line/bar represents the position of a gene, and the width of each line/bar is 
proportional to the size of each gene.  Three highly conserved genes (CTSB, BE072524, 
and HARL2754) surrounding the defensin clusters in the chicken, mouse, and human 
were connected by solid lines. The position of the α-defensin locus (DEFA) was indicated 
as an open square. Note that the human θ-defensin pseudogene resides in the DEFA locus. 
The positions and orders of defensin genes in human and mouse were drawn based on the 
genome assemblies released in July 2003 and October 2003, respectively. Abbreviations: 
GGA, chicken chromosome; MMA, mouse chromosome; HSA, human chromosome; Tel, 
telomere; Cen, centromere. 
 
 
 
 
 
 69
 
Table 1. Identification of chicken β-defensins 
 
Gene Size (bp)3 Gene EST1,2 HTGS WGS 
E 1 I 1 E 2 I 2 E 3 I 3 E 4 
Gal1 BX260462 AC110874 AADN01058097 70 972 88 482 127 496 217 
Gal2 BX540940 AC110874 AADN01058097 66 1113 143 183 121 674 204 
Gal3  AC110874 AADN01058097 
AADN01058096   53 980 109 1180 215 
Gal4 BU451960  AADN01058096   136 461 127 117 141 
Gal5 BU389548  AADN01058096   290 445 127 355 187 
Gal6 CF251501 AC110874 AADN01058097 
AADN01058098 52 704 86 705 130 249 234 
Gal7 CF251115 AC110874 AADN01058098 50 656 86 201 130 234 248 
Gal8 BU242665 AC110874 AADN01058098 71 915 91 259 134 706 494 
Gal9 BX270804 AC110874 AADN01058098   220 1592 130 781 343 
Gal10 AW198592 AC110874 AADN01058099   118 268 133 1719 381 
Gal11 BM440069 AC110874 AADN01058101   63 966 129 1001 460 
Gal12 BX257296 AC110874 AADN01058102   84 396 420   
Gal13  AC110874 AADN01058102   61 1016 118 3322 91 
 
1 Abbreviations: EST, expressed sequence tag; HTGS, high throughput genomic 
sequence; WGS, whole-genome shortgun sequence; E, exon; I, intron. 
2 One EST sequence entry is given only for the exemplary purpose. In each case, more 
than two independent EST sequences have been found, except for Gal3 and Gal13, 
both of which have no EST sequences. Gal3 was found through homology cloning [23], 
and Gal13 was predicted by us from the genomic sequence. 
3 All Gal genes are predicted to consist of four exons separated by three introns, except 
for Gal12, whose last two exons are fused together.  The absence of additional 
sequence information at the 5’-untranslated regions of the cDNA sequences prevented 
prediction of the sizes of first exon and intron for Gal 3-5 and Gal 9-13 genes. 
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Table 2. Primer sequences used for RT-PCR analysis of novel chicken β-defensins 
 
Primer Sequence Product Size (bp) Gene 
Sense Antisense cDNA Genomic 
Cycles 
Used 
Gal4 CATCTCAGTGTCGTTTCTCTGC  ACAATGGTTCCCCAAATCCAAC  321 899 36 
Gal5 CTGCCAGCAAGAAAGGAACCTG  TGAACGTGAAGGGACATCAGAG  300 1100 36 
Gal6 AGGATTTCACATCCCAGCCGTG  CAGGAGAAGCCAGTGAGTCATC  249 1203 36 
Gal7 CTGCTGTCTGTCCTCTTTGTGG  CATTTGGTAGATGCAGGAAGGA  230 665 35 
Gal8 ACAGTGTGAGCAGGCAGGAGGGA CTCTTCTGTTCAGCCTTTGGTG 261 967 35 
Gal9 GCAAAGGCTATTCCACAGCAG AGCATTTCAGCTTCCCACCAC 211 1802 33 
Gal10 TGGGGCACGCAGTCCACAAC ATCAGCTCCTCAAGGCAGTG 298 2285 33 
Gal11 ACTGCATCCGTTCCAAAGTCTG TCGGGCAGCTTCTCTACAAC 301 1299 33 
Gal12 CCCAGCAGGACCAAAGCAATG GTGAATCCACAGCCAATGAGAG 335 731 36 
Gal13 CATCGTTGTCATTCTCCTCCTC  ACTTGCAGCGTGTGGGAGTTG 175 4514 50 
GAPDH GCACGCCATCACTATCTTCC CATCCACCGTCTTCTGTGTG 356 876 30 
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4.1    Abstract 
 
Cathelicidins comprise a family of antimicrobial peptides sharing a highly conserved 
cathelin domain. Here we report that the entire chicken genome encodes three 
cathelicidins, namely fowlicidins 1-3, which are densely clustered within a 7.5-kb 
distance at the proximal end of chromosome 2p.  Each fowlicidin gene adopts a four-
exon, three-intron structure, typical for a mammalian cathelicidin. Phylogenetic analysis 
revealed that fowlicidins and a group of distantly related mammalian cathelicidins known 
as neutrophilic granule proteins are likely to originate from a common ancestral gene 
prior to the separation of birds from mammals, whereas other classic mammalian 
cathelicidins may have been duplicated from the primordial gene for neutrophilic granule 
proteins after mammals and birds are diverged. Similar to ovine cathelicidin SMAP-29, 
putatively mature fowlicidins displayed potent and salt-independent activities against a 
range of Gram-negative and Gram-positive bacteria, including antibiotic-resistant strains, 
with minimum inhibitory concentrations in the range of 0.4-2.0 µM for most strains. 
Fowlicidin-1 and -2 also showed cytotoxicity, with 50% killing of mammalian 
erythrocytes or epithelial cells in the range of 6-40 µM. In addition, two fowlicidins 
demonstrated a strong positive cooperativity in binding lipopolysaccharide (LPS), 
resulting in nearly complete blockage of LPS-mediated proinflammatory gene expression 
in RAW264.7 cells. Taken together, fowlicidin-1 and -2 are clearly among the most 
potent cathelicidins that have been reported. Their broad-spectrum and salt-insensitive 
antibacterial activities, coupled with their potent LPS-neutralizing activity, make 
fowlicidins excellent candidates for novel antimicrobial and anti-sepsis agents. 
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4.2    Introduction  
 
Cationic antimicrobial peptides comprise a large group of gene-encoded molecules 
that have been discovered in virtually all species of life, playing a critical role in innate 
host defense and disease resistance [1-4]. Two major families of antimicrobial peptides 
exist in mammals, namely defensins and cathelicidins. Whereas defensins are 
characterized by the presence of six cysteines at well-defined positions [5, 6], all 
cathelicidins share a highly conserved “cathelin” pro-sequence at the N-terminus, 
followed by diversified, cationic mature sequences at the C-terminus [7-9]. Cathelicidins 
are most abundantly present in the granules of phagocytic cells and also to a lesser extent 
in many other cell types such as mucosal epithelial cells and skin keratinocytes [7-9].  
Upon activation, most cathelicidin precursors are proteolytically cleaved to release 
the cathelin domain and the C-terminal mature peptides with antimicrobial activities, 
although the unprocessed or differentially processed forms are often found in the 
biological fluids where cathelicidins are expressed [8, 9]. The physiological role of the 
cathelin domain or uncleaved precursors remains elusive, but is more likely to be 
involved in immune modulation other than just bacterial killing [10, 11]. 
In addition to their ability to directly kill a wide range of bacteria, fungi, and 
enveloped viruses, mature cathelicidins are actively involved in various phases of host 
defense. Certain cathelicidins are found to chemoattract and activate a variety of immune 
cells, inhibit NADPH oxidase, kill activated lymphocytes, and promote angiogenesis and 
wound healing [1, 8, 9]. Consistent with their critical role in host defense and disease 
resistance, aberrant expression of cathelicidins are often associated with various disease 
processes. For example, LL-37/hCAP-18 deficiency correlates with recurrent skin 
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infections in the atopic dermatitis patients [12] and chronic periodontal disease in the 
morbus Kostmann patients [13]. Similarly, deletion of the cathelicidin gene (CRAMP) in 
mice resulted in a loss of protection against skin infection by Group A Streptococcus [14] 
or oral infection with murine enteric pathogen Citrobacter rodentium [15]. Conversely, 
local or systemic administration of cathelicidins conferred enhanced protection against 
experimental infections [16-20]. 
A common mechanism by which cathelicidins kill bacteria appears to be mediated 
through physical interactions with negatively charged microbial membrane phospholipids, 
followed by membrane disruption [3, 21]. Many cathelicidins exhibit LPS-binding 
activity, and the binding affinity is often positively correlated with their antibacterial 
activity [7]. Because of this physical mechanism, these peptide antibiotics are equally 
effective in killing both drug-resistant and susceptible strains with little possibility of 
developing resistance [3, 7]. One side-effect commonly associated with cathelicidins is 
their cytotoxicity to mammalian cells; however, the concentrations that are required to 
exert an appreciable degree of cytolytic effect are often much higher than the 
microbicidal concentrations [7].  
To date, cathelicidins have been discovered in a range of mammalian species [8, 9]. 
In contrast to the vast majority of “classic” cathelicidins, P15 in rabbits [22] and 
neutrophilic granule protein (NGP)2 in mice [23] are distantly related to classic 
cathelicidins with less homology in the cathelin domain. Hagfish was also found recently 
to contain two cathelicidin-like sequences [24]. However, the evolutionary relationship of 
these cathelicidins remains uncertain.  
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Following our genome-wide computational screening and molecular cloning, here we 
report identification and functional analysis of the complete repertoire of the cathelicidin 
gene family in the chicken. Discovery of these non-mammalian cathelicidins helped 
reveal for the first time the origin and evolution of mammalian cathelicidins. Our data 
clearly suggested that fowlicidins and mammalian NGPs are likely to originate from a 
common ancestral gene prior to the separation of birds from mammals and that other 
classic mammalian cathelicidins may have been duplicated from the NGP gene after the 
split of mammals and birds. Moreover, a series of functional analyses indicated that these 
chicken cathelicidins are among the most efficacious cathelicidins that have been 
identified to date with potent antibacterial and LPS-neutralizing activities, making them 
attractive candidates as novel antimicrobial and anti-sepsis agents. 
 
4.3    Experimental procedures  
 
Computational Search for Novel Chicken Cathelicidins - To identify potential novel 
cathelicidins in the chicken, all known cathelicidin peptide sequences discovered in the 
hagfish and mammals were individually queried against the translated chicken expressed 
sequence tags (EST), nonredundant sequences (NR), unfinished high throughput genomic 
sequences (HTGS), and whole genome shotgun sequences (WGS) in GenBank by using 
the TBLASTN program [25] as we described [26-28]. All potential hits were then 
examined for presence of the characteristic cathelin domain, including the highly 
conserved four cysteines. If necessary, the genomic sequences containing chicken 
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cathelicidin genes were retrieved from GenBank to predict the exon sequence and 
genomic structure by using GenomeScan [29].  
 
Cloning of the Chicken Fowlicidin Genes - Because no complete genomic sequence is 
available in GenBank for any of the three fowlicidin genes, the missing sequence of each 
gene was cloned separately from chicken genomic DNA that was isolated from liver 
using a genomic DNA isolation kit (Zymo Research, Orange, CA). The first exon/ intron 
sequence of the fowlicidin-2 gene that  is missing in the WGS sequence 
(AADN01005055) was cloned by using a genome walking approach, namely vectorette 
PCR, as previously described [30, 31]. Briefly, chicken genomic DNA was digested 
separately with the blunt-end restriction enzymes (Dra I, EcoR V, Puv I, Rsa I, and Stu I), 
followed by ligation with annealed, bubble oligonucleotides (5’-
CAAGGGAGGACGCTGTCTGTCGAAGGTAAGGAACGGACGAGAGAAGGGAGA
G-3’), and 5’-CTCTCCCTTCTCGAATCGTAACCGTTCG 
TACGAGAATCGCTGTCCTCTCCTTG-3’). Subsequent PCR was performed by using 
the forward primer indicated in the underlined region of the bubble oligonucleotide and a 
gene-specific reverse primer. Nested PCR was further performed with the same forward 
primer and a second gene-specific reverse primer. Two rounds of vectorette PCR were 
performed to obtain a total of 1.8 kb upstream sequence of the fowlicidin-2 gene. 
Because only partial sequence of the last exon of the fowlicidin-1 gene is present in 
AADN01081708, the entire fowlicidin-1 gene sequence was directly cloned from 
genomic DNA by PCR using the primers (Forward: 5’-
GTTTCCGCATTGCCCAACTTCAG-3’; Reverse: 5’-
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GGAACAGTGCTAACAGTGGCTC-3’), which are located in the first and last exons 
flanking the open reading frame, according to the EST Sequence. The missing first intron 
sequence of the fowlicidin-3 gene, i.e., the gap between AADN01005055 and 
AADN01005056, was cloned from chicken genomic DNA by PCR using primers 
(Forward: 5’-GCTGTGGACTCCTACA ACCAAC-3’; Reverse: 5’-
TTGAGGTTGTGCA GGGAGCTGA-3’) located in two flanking exons. All PCR 
products were recovered from agarose gel, ligated into pGEM T-Easy Vector (Promega, 
USA), and sequenced from both directions.  
 
Assembly of the Chicken Cathelicidin Gene Cluster - To confirm the orientation of 
three fowlicidin genes on the chromosome, additional PCR reactions were performed to 
clone the intergenic sequences with chicken genomic DNA and combinations of gene-
specific primers located in the first and last exons of each fowlicidin gene. The DNA 
sequence between fowlicidin-1 and fowlicidin-2 was obtained by using the primers 
(Forward: 5’-CGCTGGTCATCAGGACTGTGA T-3’; Reverse: 5’-
CCATCGTGTCTCCATTCTA TC-3’), while the sequence between fowlicidin-2 and 
fowlicidin-3 was obtained by using the primers (Forward: 5’-CACCGTGTTGATGGCC 
ACTGG-3’; Reverse: 5’-TGAGGCCACCGAGTG TCACCT-3’). PCR products were 
subsequently cloned into pGEM T-Easy Vector and sequenced from both directions. No 
other primer combinations yielded any PCR products. 
To generate a continuous, gap-free cathelicidin gene cluster, three WGS sequences 
containing fowlicidin genes (AADN01005055, AADN01005056, and AADN01081708) 
were retrieved from GenBank and annotated together with our newly cloned intra- and 
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intergenic sequences. Structures of fowlicidin genes were determined by comparing their 
cDNA sequences with the genomic contig that we assembled. Chromosomal location of 
the chicken cathelicidin gene cluster was revealed by using the Map Viewer Program 
(http://www.ncbi.nlm.nih.gov/ mapview/) in the most current chicken genome assembly 
(Build 1.1) released on July 1, 2004. 
 
Alignment and Phylogenetic Analysis of Chicken Cathelicidins - Multiple sequence 
alignment was constructed by using the ClustalW program (version 1.82) [32]. The 
phylogenetic tree was constructed using the neighbor-joining method [33] by calculating 
the proportion of amino acid differences (p-distance) among all known cathelicidin 
precursors with and without the last exon sequence. The reliability of each branch was 
tested by 1000 bootstrap replications. 
 
Peptide Synthesis - Given that valine is the preferred cleavage site for elastase in the 
processing and maturation of bovine and porcine cathelicidins [34, 35], we reasoned that 
the first valine in the fourth exon of fowlicidin-1 and -2 (Fig. 1) is likely to be cleaved by 
chicken elastase. Therefore, putative mature fowlicidin-1 (RVKRV 
WPLVIRTVIAGYNLYRAIKKK) and -2 (LVQR 
GRFGRFLRKIRRFRPKVTITIQGSARF) were chemically synthesized by SynPep 
(Dublin, CA), and a sheep cathelicidin, SMAP-29 (RGLR 
RLGRKIAHGVKKYGPTVLRIIRIA-NH2) was synthesized by Bio-Synthesis (Lewisville, 
TX) by the standard solid-phase synthesis method. All peptides were purified to >95% 
purity through reverse phase-HPLC. The mass and purity of each peptide was confirmed 
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by the matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry using the Voyager DE-PRO instrument (Applied Biosystems, Foster City, 
CA) housed in the Recombinant DNA/Protein Core Facility of Oklahoma State 
University. The molecular masses of three peptides are as follows: fowlicidin-1 
(calculated: 3141.9 and observed: 3141.6), fowlicidin-2 (calculated: 3760.6 and observed: 
3760.1), and SMAP-29 (calculated: 3199.0 and observed: 3198.7).   
 
Bacterial Culture - Gram-negative bacteria (Escherichia coli ATCC 25922, E. coli 
O157:H7 ATCC 700728, Salmonella typhimurium ATCC 14028, Klebsiella pneumoniae 
ATCC 13883, and Pseudomonas aeruginosa ATCC 27853), and Gram-positive bacteria 
(L. monocytogenes ATCC 19115 and Staphylococcus aureus ATCC 25923) were 
purchased from either ATCC (Manassas, VA) or MicroBiologics (St. Cloud, MN) and 
tested individually against fowlicidins and SMAP-29. Three multidrug-resistant bacterial 
strains (S. typhimurium DT104 ATCC 700408, S. aureus ATCC BAA-39, and S. aureus 
ATCC 43300) were also purchased from ATCC and used in the antibacterial testing. All 
bacteria were maintained on trypticase soy agar (TSA) plates. Fresh colonies were 
cultured and subcultured in trypticase soy broth (TSB) with shaking at 250 rpm at 37oC 
in a shaking incubator. 
 
Antibacterial Assays - Standard colony counting assay was used to determine the 
antibacterial activity of fowlicidins as previously described [36]. Briefly, overnight 
cultures of bacteria were subcultured for additional 3-5 h at 37oC in TSB to the mid-
logarithmic phase, washed once with 10 mM sodium phosphate buffer, pH 7.4, and 
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suspended to 4×105 colony forming units (CFU)/ml in the same buffer.  Bacteria (90 µl) 
were dispensed into 96-well microtiter plates, followed by addition of 10 µl of serial 
twofold dilutions of peptides in duplicate. After 2-h incubation at 37oC, surviving 
bacteria were counted (CFU/ml) after serial plating onto TSA plates and overnight 
incubation. Minimum inhibitory concentration (MIC90) of individual peptides against 
each bacterial strain was determined as the lowest concentration that reduced bacterial 
growth by 90%.   
For the kinetics of bacterial killing, fowlicidin-1 (0.1 µM), fowlicidin-2 (0.16 µM), 
and SMAP-29 (0.1 µM) at MIC90 concentrations were incubated separately with E. coli 
ATCC 25922 at 37oC in 10 mM sodium phosphate buffer, pH 7.4. The reaction was 
stopped by addition of ice-cold PBS at 0, 5, 10, 15, 20, 30, and 60 min and plated 
immediately for counting viable bacteria. To study the effect of salinity on the 
antimicrobial activity, fowlicidin-1 (0.1 µM) and fowlicidin-2 (0.16 µM) were incubated 
separately with E. coli ATCC 25922 for 2 h with different concentration of NaCl (0, 25, 
50, 100, and 150 mM) in 10 mM sodium phosphate buffer, pH 7.4. Surviving bacteria 
were counted, following overnight incubation on TSA plates. 
To examine the antibacterial spectrum of each peptide, a modified broth 
microdilution assay was used essentially as described [37]. Briefly, bacteria were 
subcultured to the mid-log phase, washed with 10 mM sodium phosphate buffer and 
suspended to 5 × 105 CFU/ml in 1% cation-adjusted Mueller Hinton broth (MHB) (BBL, 
Cockeysville, MD) with and without 100 mM of NaCl. Bacteria (90 µl) were then 
dispensed into 96-well plates, followed by addition in duplicate of 10 µl of serially 
diluted peptides in 0.01% acetic acid. Because of poor growth of P. aeruginosa ATCC 
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27853 in 1% MHB, this strain was grown in 10% cation-adjusted MHB with peptides in 
the presence and absence of 100 mM NaCl. After overnight incubation at 37oC, the MIC 
value of each peptide will be determined as the lowest concentration that gave no visible 
bacterial growth.  
 
Hemolysis Assay - The hemolytic activities of fowlicidins were determined essentially 
as described [38, 39]. Briefly, fresh human and chicken blood were collected, washed 
twice with PBS, and diluted to 0.5% in PBS with and without addition of 10% FBS, 
followed by dispensing 90 µl into 96-well plates. Different concentrations of peptides (10 
µl) dissolved in 0.01% acetic acid were added in duplicate to cells and incubated at 37oC 
for 2 h. Following centrifugation at 800 × g for 10 min, the supernatants were transferred 
to new 96-well plates and monitored by measuring the absorbance at 405 nm for released 
hemoglobin. Controls for 0 and 100% hemolysis consisted of cells suspend in PBS only 
and in 1% Triton X-100, respectively. Percent hemolysis (%) was calculated as [(A405nm, 
peptide – A405nm, PBS) / (A405nm, 1% Triton X-100 – A405nm, PBS)] × 100. The effective concentration 
(EC50) was defined as the peptide concentration that caused 50% lysis of erythrocytes. 
 
Cytotoxicity Assay - The cytotoxic effect of fowlicidins on mammalian cells was 
measured by using the alamarBlue dye (Biosource), which has been shown to be 
equivalent to the classic MTT-based assay [40]. Madin-Darby canine kidney (MDCK) 
epithelial cells were purchased from ATCC and maintained in DMEM with 10% FBS. 
MDCK cells were seeded into 96-well plates at 1.5 × 105/well. Following overnight 
growth, the cells were washed once with DMEM, followed by addition of 90 µl of fresh 
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DMEM with or without 10% FBS, together with 10 µl of serially diluted peptides in 
0.01% acetic acid in duplicate. After incubation for 18 h, 10 µl of alamarBlue dye was 
added to cells for 6 h at 37oC in a humidified 5% CO2 incubator.  The fluorescence of dye 
was read with excitation at 545 nm and emission at 590 nm.  Percent cell death (%) was 
calculated as [1 – (Fpeptide – Fbackground)/(Facetic acid – Fbackground)] ×100, where Fpeptide is the 
fluorescence of cells exposed to different concentrations of peptides, Facetic acid is the 
fluorescence of cells exposed to 0.01% acetic acid only, Fbackground is the background 
fluorescence of 10% alamarBlue dye in cell culture medium without cells.  Cytotoxicity 
(EC50) of individual peptides was defined as the peptide concentration that caused 50% 
cell death. 
 
LPS Binding Assay -  The binding of LPS to fowlicidins was measured by the kinetic 
chromogenic Limulus amebocyte lysate assay (Kinetic-QCL 1000 kit; BioWhittaker, 
Walkersville, MD) as previously described [37, 41]. Briefly, 25 µl of serially diluted 
peptide were added in duplicate into 25 µl of E. coli O111:B4 LPS containing 0.5 
endotoxin units/ml and incubated for 30 min at 37oC, followed by incubation with 50 µl 
of the amoebocyte lysate reagent for 10 min. The absorbance at 405 nm was measured at 
10 and 16 min after addition of 100 µl of chromogenic substrate, Ac-Ile-Glu-Ala-Arg-p-
nitroanilide. Percent LPS binding was calculated as [(∆D1 – ∆D2 + ∆D3)/ ∆D1] × 100, 
where ∆D1 represents the difference in the absorbance between 10 and 16 min for the 
sample containing LPS only, ∆D2 represents the difference in the absorbance between 10 
and 16 min for the samples containing LPS and different concentrations of peptides, and 
∆D3 represents the difference in the absorbance between 10 and 16 min for the samples 
 83
containing different concentrations of peptides with no LPS. Hill plot was graphed as 
described [37, 41] by plotting log10 fowlicidin concentrations against log10 [FI/(1.0 -FI)], 
where FI was the fractional inhibition of LPS binding activity.  
  
Modulation of LPS-induced Proinflammatory Gene Expression by Fowlicidins - 
Mouse macrophage RAW 264.7 cells were plated in 12-well plates at 5 x 105 cells/well in 
DMEM with 10% FBS and allowed to grow overnight. The cells were pretreated for 30 
min with 1, 5, and 20 µM of fowlicidin-1, fowlicidin-2, and SMAP-29 in duplicate, 
followed by stimulation with 100 ng/ml LPS from E. coli O114:B4 (Sigma) for 4 h. The 
supernatant was removed and total RNA was isolated from cells using TRIzol (Invitrogen) 
according to the manufacturer’s instructions. The first strand cDNA from 1.5 µg of each 
RNA sample was synthesized at 42oC for 30 min by using QuantiTect® Reverse 
Transcription Kit (Qiagen), which includes removal of genomic DNA contamination 
prior to cDNA synthesis.  
The first-strand cDNA of each sample was then used as a template for subsequent 
real-time PCR amplification by using QuantiTect® SYBR Green qRT-PCR Kit (Qiagen) 
and MyiQ® Real-Time PCR Detection System (Bio-Rad). Three common 
proinflammatory cytokines and chemokines, namely interleukin (IL)-1β, CC chemokine 
ligand 2 (CCL2)/MCP-1, and CCL3/MIP-1α, were selected.  All primers were designed 
to expand at least an intron sequence (Table I). The PCR reaction was set up in a total 
volume of 15 µl containing 0.4 µM of each primer and 0.2 µg of the first-strand cDNA. 
PCR cycling conditions were as follows: 95oC for 10 min, followed by 50 cycles of 95oC 
for 15 sec, 55oC for 30 sec, and 72oC for 30 sec.  
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Gene expression levels were quantified by the comparative ∆∆CT method as 
described [42] by using β-actin as an internal standard for normalization. The ∆CT value 
was determined by subtracting the CT value of each sample from that of β-actin in the 
corresponding sample. The ∆∆CT values were further calculated by subtracting the 
highest mean ∆CT value as an arbitrary constant from all other ∆CT values. Relative gene 
expression levels were calculated using the formula 2-∆∆Ct. The presence of contaminating 
genomic DNA was determined by including a no-reverse transcriptase control and signal 
generated by primer dimers was determined through no-template controls. Melting curve 
analysis (55-95oC) was performed and confirmed no visible nonspecific amplification of 
any PCR products from genomic DNA or primer dimers. 
 
4.4    Results  
 
Identification of Three Novel Chicken Cathelicidin Genes - To identify potential 
cathelicidins in the chicken, all known cathelicidin peptide sequences were queried 
individually against the translated genomic and EST sequences in GenBank by using the 
TBLASTN program [25] as we previously described [26-28]. As a result, seven chicken 
EST sequences (GenBank accession numbers BX936022, BU106516, AJ393748, 
CB018183, BU420865, CR389785, and BQ484540) were identified (Table II). Three 
putative cathelicidin peptide sequences were subsequently deduced and termed 
fowlicidins 1-3. Because the N-terminal sequence including the start codon of fowlicidin-
2 was missing in GenBank, a genome walking approach known as vectorette PCR was 
performed by using chicken genomic DNA as previously described [30, 31]. As a result, 
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a 1.8-kb upstream sequence of the fowlicidin-2 gene was obtained following two rounds 
of vectorette PCR (data not shown). The missing N-terminal peptide sequence of 
fowlicidin-2 was predicted by GenomeScan [29] based on its homology with the other 
two fowlicidins.  
 Alignment of three fowlicidin peptide sequences revealed that they are highly 
homologous to each other (Fig. 1). Among all three peptides, fowlicidin-1 and -3 are 
more closely related with >90% identity throughout the entire sequence. Chicken 
cathelicidins also share a high degree of similarity with all known mammalian 
cathelicidins, particularly in the prosequence region (Fig. 1). Noticeably, four cysteines 
that are conserved in the cathelin domain of all mammalian cathelicidins are also 
invariantly spaced in three fowlicidins. These results clearly suggest that three chicken 
fowlicidins are bona fide non-mammalian cathelicidins.  
 Despite of sequence conservation at the N-terminus, fowlicidins and classic 
cathelicidins are drastically diverged at the C-terminus (Fig. 1).  Similar to classic 
cathelicidins, fowlicidins 1-3 are positively charged at the C-terminus due to the presence 
of an excess number of cationic residues (R and K). The preferred cleavage site for 
elastase in the processing and maturation of bovine and porcine cathelicidins [34, 35] also 
appears to be conserved in the chicken. Therefore, mature fowlicidins 1-3 are predicted to 
be devoid of cysteines and composed of 26, 32, and 29 amino acid residues with a net 
charge of +8, +10, and +7, respectively (Fig. 1). 
 In addition to fowlicidins, we also identified the orthologs of rabbit P15 [22] and 
mouse NGP [23] in the rat, pig, and cow, which we named rNGP, pNGP, and bNGP, 
respectively (Fig. 1). However, no NGP-like genes were found in dogs or primates. 
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Surprisingly, fowlicidins share a higher degree of similarity particularly in the signal 
sequence region with NGPs than to classic cathelicidins (Fig. 1), implying that chicken 
cathelicidins and NPGs may be more closely related. It is noted that all NGPs are highly 
conserved throughout the entire sequence among rodents and ungulates with a net 
negative charge at the C-terminus. The functional significance of such anionic sequences 
remains to be studied. 
 
Genomic Organization of the Chicken Fowlicidin Gene Cluster - A screening through 
genomic sequences in the NR, HTGS and WGS databases in GenBank identified three 
WGS sequences. AADN01081708 contains a part of the last exon sequence of the 
fowlicidin-1 gene, and AADN01005055 and AADN01005056 encode the majority of the 
fowlicidin-2 and -3 genes (Fig. 2A). The fowlicidin-1 gene was cloned from chicken 
genomic DNA by PCR using the primers located in the first and last exons, whereas the 
missing first intron sequence of the fowlicidin-3 gene, i.e., the gap between 
AADN01005055 and AADN01005056, was cloned directly by PCR with primers located 
in two flanking exons (Fig. 2A). The 5’-end of the fowlicidin-2 gene was cloned by two 
rounds of vectorette PCR as described in the previous section. Structural organizations of 
three fowlicidin genes were obtained by comparing their cDNA with genomic DNA 
sequences. As shown in Table I, all three genes are organized similarly with four exons 
separated by three introns. The first three exons encode the signal and cathelin pro-
sequences, whereas the last exon primarily encodes the mature sequences. Such 
structures are surprisingly identical to the mammalian cathelicidin genes, a clear 
indication of significant conservation during evolution. 
 87
 Annotation of AADN01005055, AADN01005056, AADN01081708, and our newly 
cloned intra- and intergenic sequences resulted in the formation a continuous, gap-free 
contig that harbors all three fowlicidin genes, which has been deposited to GenBank 
under accession number DQ092350. As shown in Fig. 2A, three fowlicidin genes are 
packed tightly in a 7.5-kb distance on the chromosome with fowlicidin-2 and -3 in a 
head-to-head orientation that is separated only by 736 bp from the stop codons of both 
genes. However, fowlicidin-1 and -2 are separated 2.4 kb from each other by a gene 
homologous to the C-terminal end of vesicle-associated, calmodulin kinase-like kinase 
(CamKV) (GenBank accession no. NP_076951). Chromosomal location of the chicken 
cathelicidin gene cluster was further revealed by using the Map Viewer Program. 
AADN01005055 and AADN01005056 were found to locate on the p arm of chromosome 
2 that are less than 3.5 Mb from the proximal end in the current chicken genome 
assembly (Build 1.1) released on July 1, 2004, but AADN01081708 remains unmapped. 
 
Comparative and Evolutionary Analyses of Vertebrate Cathelicidins - Identification 
of three chicken fowlicidins provides an excellent opportunity to study the evolutionary 
relationship of mammalian cathelicidins. We first examined physical locations of the 
cathelicidin gene clusters across several phylogenetically distant vertebrate species. As 
shown in Fig. 2B, the cathelicidin genes are located in the syntenic regions flanking an 
evolutionarily conserved gene, Kelch-like 18 (KLHL18) (NP_071737) across rodents, 
dogs, and humans, clearly indicating that cathelicidins in mammals and birds share a 
common ancestor. It is noteworthy that the chicken CamKV gene is absent in syntenic 
regions in mammals (Fig. 2B).  
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 We then performed the phylogenetic analysis of fowlicidins together with all known 
mammalian cathelicidins and two recently identified hagfish cathelicidins using the 
neighbor-joining method [33] by calculating the proportion of amino acid differences. All 
vertebrate cathelicidins clearly formed three distinct clusters with two hagfish peptides 
located in a separate clade from others (Fig. 3). Supported by a bootstrap value of 56%, 
fowlicidins clustered with NGPs, suggesting that fowlicidins and NGPs are likely to 
originate from a common ancestor prior to the separation of birds from mammals. This is 
further supported by the close proximity of fowlicidins and NGPs with KLHL18 on 
chromosomes (Fig. 2B). All classic mammalian cathelicidins comprised a separate cluster 
supported by a bootstrap value of 99% (Fig. 3) and are located more than 500 kb away 
from KLHL18 and NGP, implying that classic cathelicidins are likely to be duplicated 
from NGPs after the mammal-bird split. Apparent missing of NGPs in the dog, 
chimpanzee, and human genomes (data not shown) suggested that the NGP lineage was 
lost after canines and primates diverged from other mammals.  
 However, it is also possible that two different primordial genes for NGPs/fowlicidins 
and classic cathelicidins were present in the common ancestor of aves and mammals. 
Both gene lineages are preserved in most mammals, but the classic cathelicidin lineage 
was lost in aves after they split from mammals. Because two hagfish cathelicidins 
are too divergent, it is impossible to point out the evolutionary relationship of fish 
cathelicidins with their avian and mammalian homologs. Availability of genomic 
sequences of additional phylo-genetically distant lower vertebrate species is expected to 
help bridge the gap. 
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Antibacterial Properties of Fowlicidins - To test antibacterial properties of chicken 
cathelicidins, putatively mature fowlicidin-1 and -2 were synthesized commercially by 
the standard solid phase synthesis method and purified to >95% purity. A reference strain 
of E. coli ATCC 25922 was tested by using the colony counting assay as previously 
described [36]. As shown in Fig. 4A, fowlicidin-1 and -2 displayed a MIC90 of 65 nM 
and 180 nM, respectively, against E. coli. In fact, when compared directly with SMAP-29, 
which is the most potent cathelicidin that has been reported thus far [7], both fowlicidin-1 
and -2 showed comparable antibacterial potency, implying the promising therapeutic 
potential of these two chicken cathelicidins. Furthermore, similar to SMPA-29, both 
fowlicidins showed a rapid killing of E. coli with the maximum killing occurring at 30 
min at MIC90 concentrations (Fig. 4B), reinforcing the notion that both fowlicidins kill 
bacteria most likely through physical membrane disruption. However, unlike many 
antimicrobial peptides whose antimicrobial activities are inhibited by salt at physiological 
concentrations [36-38, 43, 44], fowlicidin-1 and -2 maintained their activities up to 150 
mM NaCl (Fig. 4C), implying their potential for systemic therapeutic applications. It is 
noted that we did not observe any obvious synergistic effect of two fowlicidin peptides in 
killing E. coli when applied together (data not shown). 
To test the antibacterial spectrum of fowlicidins, six Gram-negative and four Gram-
positive bacterial strains were used in a modified broth microdilution assay [37]. Both 
chicken cathelicidins were broadly effective against all bacteria tested in a salt-
independent manner, with most MIC values in the range of 0.4-2.0 µM (Table III). P. 
aeruginosa appeared to be the only exception, being slightly more resistant to fowlicidins 
with the MIC of 3-6 µM for both peptides. Strikingly, both peptides displayed 
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comparable antibacterial potency with SMAP-29 against all bacteria, although there was 
a tendency that fowlicidin-1 is slightly more efficacious than fowlicidin-2 in most cases 
(Table III). More desirably, both peptides were equally effective against antibiotic-
resistant bacterial strains, such as multidrug-resistant S. typhimurium DT104 and 
methicilin-resistant S. aureus (MRSA) (Table III). Fowlicidin-3 also showed similar 
antibacterial activities against Gram-positive and Gram-negative bacteria to fowlicidin-1 
(data not shown), but was omitted for further functional analyses because of its high 
homology with fowlicidin-1 (Fig. 1). 
 
Cytotoxicity of Fowlicidins - To evaluate the hemolytic activity of fowlicidins against 
red blood cells, freshly isolated human and chicken erythrocytes were incubated with 
fowlicidins, together with SMAP29 as a positive reference. Hemolysis was monitored by 
measuring the absorbance at 405 nm for released hemoglobin as described [38, 39]. 
Hemolytic activities of both chicken cathelicidins were similar toward human and 
chicken erythrocytes with EC50 occurring at approximately 6-10 µM and 15-20 µM for 
fowlicidin-1 and -2, respectively (Fig. 5A and 5B). Hemolytic activities of both 
fowlicidins and SMAP-29 were reduced by 2-4 fold in the presence of 10% FBS (data 
not shown).  
To further examine the cytotoxicities of fowlicidins toward mammalian epithelial 
cells, the viability of MDCK cells was measured by an alamarBlue-based, colorimetric 
method [40], following exposure to either peptide for 24 h. As shown in Fig. 5C, in the 
absence of 10% FBS, EC50 occurred in the range of 10-20 µM toward MDCK cells for 
both fowlicidins, with SMAP-29 being the most toxic. A similar trend also occurred with 
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RAW264.7 macrophage cells (data not shown). A 2- to 5-fold reduction in toxicity was 
observed in the presence of 10% FBS for all three peptides. It is noted that the 
cytotoxicities of fowlicidins toward mammalian host cells are at least several fold higher 
than their MIC values toward bacteria (compare Table III and Fig. 5), suggestive of the 
therapeutic potential of two fowlicidins. Nevertheless, a further reduction of their toxicity 
through rational mutagenesis will be more desirable. 
 
LPS Binding and Host Gene Modulatory Activities of Fowlicidins - To test the 
potential of fowlicidins as anti-sepsis agents, a chromogenic Limulus amebocyte lysate 
assay was used to measure the binding of LPS to fowlicidins by the competitive 
inhibition of LPS-induced procoagulant activation as described [37, 41]. As shown in Fig. 
6A, typical sigmoidal curves of LPS binding activity were observed for both peptides, 
which exhibited a similar LPS binding efficiency with 50% binding occurring at 7.5 µM 
and 8.6 µM for fowlicidin-1 and -2, respectively. Both peptides completely inhibited the 
LPS procoagulant activity at 10-15 µM concentrations. Because the sigmoidal shapes 
imply cooperativity, we also graphed the data on a Hill Plot (Fig. 6B). The Hill plot 
coefficients (slopes) were calculated to be 2.44 and 3.22 for fowlicidin-1 and -2, 
respectively, suggesting the presence of cooperative LPS binding sites possibly on each 
peptide molecule for both peptides. These results are reminiscent of SMAP-29 and LL-37 
with multiple intramolecular LPS binding sites that function cooperatively to allow 
peptides to bind to LPS with high affinity [37, 41]. 
To further evaluate whether binding of fowlicidins to LPS can neutralize LPS-
induced proinflammatory responses, RAW264.7 macrophage cells were stimulated with 
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LPS in the presence of different concentrations of peptides, followed by evaluation of 
proinflammatory cytokine/chemokine gene expression by real time reverse transcriptase-
PCR. Fowlicidin-1 and -2, when applied up to 20 µM in the absence of LPS, did not alter 
gene expression. However, they blocked LPS-induced expression of IL-1β and CCL-
2/MCP-1 in a dose-dependent fashion (Fig. 6C and 6D). The same trend also occurred 
with CCL-3/MIP-1α for both peptides (data not shown). In fact, fowlicidins inhibited the 
expression of all three genes by >90% at 20 µM (Fig. 6C and 6D). To our surprise, albeit 
with in vitro LPS-binding activity [41], SMAP-29, even at 20 µM, failed to suppress the 
expression of any of the three proinflammatory genes that we examined. Collectively, 
these data strongly suggested the potential of fowlicidin-1 and -2 as both antibacterial and 
anti-sepsis agents. It is noted that all three peptides, when applied at 20 µM, caused only 
minimal, < 5% cell death to RAW264.7 cells in the presence of 10% FBS (data not 
shown). 
 
4.5    Discussion  
 
Three chicken cathelicidins consist of linear cationic sequences at the C-termini, 
which are expected to be freed from the cathelin domain to become biologically active. 
Indeed, putatively mature fowlicidins possess potent antibacterial activities (Fig. 4 and 
Table III). Although we suspected that valine on the fourth exon of fowlicidins (Fig. 1) is 
likely to be the processing site for chicken elastase-like protease as in the case of bovine 
and porcine cathelicidins [34, 35], the protease and exact cleavage site for fowlicidins 
need to be experimentally confirmed.  
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In the course of screening for chicken cathelicidins, we also identified NGPs in rats, 
pigs and cows that are highly homologous to P15s in rabbits [22] and NGP in mice [23] 
(Fig. 1). These NGP-like proteins appear to be evolutionarily conserved only in glires and 
ungulates, but not in dogs and primates. In spite of relatively low homology in the 
cathelin domain with the majority of other mammalian cathelicidins, NGPs share similar 
tissue expression pattern [22, 23], chromosomal location (Fig. 2B), gene structure (data 
not shown), and antimicrobial activities [22] to classic mammalian cathelicidins, and 
therefore, clearly belong to the cathelicidin family. Identification of three fowlicidins, 
which are more closely related to NGPs (Fig. 1 and 3), suggested that the ancestral gene 
for fowlicidins/NGPs arose in the common ancestor of mammals and birds, which may 
have further given rise to classic mammalian cathelicidins as a result of gene duplication 
after the mammal-bird split. Classic cathelicidins must have been duplicated from NGPs 
prior to the divergence of mammals from each other, because of a high degree of 
homology within classic cathelicidins particularly in the cathelin domain. Apparently, 
independent duplications have occurred after mammals were separated from each other, 
which is supported by species-specific clustering and presence of a varied number of 
classic cathelicidins in most cases (Fig. 3). For example, ungulates have multiple 
cathelicidins, whereas most other mammals have one or very few members.  
As for the origin of three chicken cathelicidins, fowlicidin-1 and -3 are apparently a 
result of gene duplication, because of significant homology across the entire open reading 
frame (Fig. 1). Furthermore, the intron sequences of these two cathelicidin genes are 
highly similar (data not shown). Fowlicidin-2 also shares significant homology in the first 
three exons with fowlicidin-1 and -3, but diverged greatly in the last exon encoding the 
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mature sequence (Fig. 1). However, alignment of the last intron and exon nucleotide 
sequences of three fowlicidin genes revealed approximately 45% identity (data not 
shown). This suggested that, the entire fowlicidin-2 gene may have been duplicated 
directly from fowlicidin-1 or -3, but not a result of exon shuffling [45], which probably 
gave rise to multiple cathelicidins with drastic sequence divergence in the last exon in 
ungulates.  
Although P15s is unique in that its does not undergo proteolytic processing when 
released [22], it will be interesting to see whether it is also true with other mammalian 
NGPs. The presence of valines in the fourth exons of NGPs in the pig and rat at 
equivalent elastase cleavage site raises the possibility that at least some NGPs may be 
enzymatically processed upon activation (Fig. 1). However, the C-terminal peptides of 
NGPs are all negatively charged, as opposed to classic cathelicidins with cationic 
sequences. Therefore, it will be interesting to study the processing and biological roles of 
these NGPs. Because of the existence of two cathelicidins (NGP and CRAMP) in mice as 
opposed to a single cathelicidin (LL-37/hCAP-18) in humans, extrapolation of the data 
from CRAMP-deficient mouse to the human system needs to be more prudent. 
During the preparation of our manuscript, the sequences identical to fowlicidin-1 and 
-2 have been reported independently [46, 47]. Similar to most mammalian cathelicidins, 
fowlicidin-1 and -2 were shown to be expressed primarily in bone marrow, but none of 
the functional information has been provided [46, 47]. Our data clearly indicated that 
putatively mature fowlicidins are clearly among the most potent cathelicidins discovered 
to date, killing a variety of bacteria at <2 µM (Table III). This is perhaps not surprising, 
given the fact that chicken heterophils, which are equivalent to mammalian neutrophils 
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and likely the store sites of fowlicidins, lack myeloperoxidase and depends primarily on 
non-oxidative mechanisms for antimicrobial activity [48]. Unlike many cationic 
antimicrobial peptides that are inactivated at physiological concentrations of salt, 
fowlicidins maintained antibacterial activity in the presence of high NaCl (Fig. 4C and 
Table III). Salt-independent killing of bacteria of fowlicidins may offer an attractive 
therapeutic option for cystic fibrosis and Crohn’s disease, both of which are associated 
with aberrant local expression or inactivation of antimicrobial peptides [49-51].  
In summary, discovery and functional characterization of these chicken cathelicidins 
offer new insights on the evolution of mammalian cathelicidins. Potent, broad-spectrum, 
salt-independent antibacterial activities with strong LPS-neutralizing activity make 
fowlicidins excellent candidates as antimicrobial and anti-sepsis agents. Structure-activity 
relationship studies of these peptides aiming at potentiating their antimicrobial and LPS-
neutralizing activities while further reducing their toxicities are currently ongoing. 
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4.8    Footnotes  
 
* This work was supported by the Oklahoma Center for the Advancement of Science 
and Technology Grant HR03-146 and Oklahoma Agricultural Experiment Station project 
H-2507. 
The nucleotide sequences reported in this paper have been submitted to the 
GenBankTM/EMBL Data Bank with accession numbers DQ092350, DQ092351, 
DQ092352, and DQ092353. 
2 The abbreviations used are: NGP, neutrophilic granule protein; EST, expressed 
sequence tag; HTGS, high throughput genomic sequence; WGS, whole-genome shortgun 
sequence; CFU, colony forming units; TSB, trypticase soy agar; MHB, Mueller Hinton 
broth; MIC90, minimum inhibitory concentration of an antimicrobial that reduces 
bacterial growth by 90%; EC50, 50% effective concentration; LPS, lipopolysaccharide; 
MDCK, Madin-Darby canine kidney cells; SEM, standard error of the mean. 
. 
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TABLE I. Primer sequences used for real-time RT-PCR analysis of murine 
cytokines and chemokines 
Primer Sequence Product Size (bp) Gene 
Forward  Reverse cDNA Genomic 
IL-1β AGAATCTATACCTGTCCTGTGT TGTGCTCTGCTTGTGAGGTG 916 195 
CCL2 ACAAGAGGATCACCAGCAGC CTGAAGACCTTAGGGCAGATG 511 186 
CCL-3 CACGCCAATTCATCGTTGAC CATTCAGTTCCAGGTCAGTG 372 147 
β-actin GGAGATTACTGCTCTGGCTC CTCCTGCTTGCTGATCCACA 264 139 
 
 
 
TABLE II.  Identification of chicken fowlicidins 
 
The chicken genome contains three cathelicidin genes, namely fowlicidins 1-3, encoded 
by expressed sequence tags (EST) and whole genome shotgun sequences (WGS) as 
indicated. Each fowlicidin gene consists of four exons (E) separated by three introns (I). 
The sizes of the first and last exons are given according to the coding sequences without 
the 5’- and 3’-untranslated regions being counted. Note that the first three exons are 
100% identical between fowlicdin-1 and fowlicdin-3, except for exon 4, which encodes 
different mature sequences. 
 
Gene Size (bp) 
Gene EST WGS 
E 1 I 1 E 2 I 2 E 3 I 3 E 4 
fowlicidin-1 
BX936022 
BU106516 
AY534900 
 
AADN01081708 168 537 108 84 84 99 87 
fowlicidin-2 
AJ393748 
CB018183 
BU420865 
 
AADN01005055 168 901 108 70 84 293 105 
fowlicidin-3 CR389785 AADN01005055 AADN01005056 168 535 108 84 84 99 96 
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TABLE III. Antibacterial spectrum of fowlicidins against Gram-negative and 
Gram-positive bacteria 
 
Mid-log phase bacteria (5 x 105 CFU/ml) in 1% cation-adjusted Muller Hinton broth 
(MHB) were incubated overnight with serial twofold dilutions of peptides in the presence 
or absence of 100 mM NaCl. The exception was P. aeruginosa ATCC 27853, which was 
incubated with peptides in 10% cation-adjusted MHB with or without addition of 100 
mM NaCl. The minimum inhibitory concentrations (MIC) of individual peptides against 
each bacterial strain were determined as the peptide concentration that gave no visible 
bacterial growth after overnight incubation. The experiments were repeated at least twice 
with essentially the same results. 
 
MIC (µM) 
Fowlicidin-1 
(NaCl, mM) 
Fowlicidin-2 
(NaCl, mM) 
SMAP-29 
(NaCl, mM) 
 
 
Bacteria 
 
 
ATCC # 
0 100 0 100 0 100 
Gram-negative: 
  E. coli 
  E. coli O157:H7 
  S. typhimurium 
  S. Typhimurium DT104 
  K. pneumoniae 
  P. aeruginosa 
 
Gram-positive:  
  L. monocytogenes 
  S. aureus 
  S. aureus (MRSA)1 
  S. aureus (MRSA) 
 
25922 
700728 
14028 
700408 
13883 
27853 
 
 
19115 
25923 
BAA-39 
43300 
 
1.59 
0.80 
0.80 
0.40 
0.40 
3.18 
 
 
0.80 
0.80 
0.40 
0.40 
 
1.59 
0.80 
1.59 
1.59 
0.80 
3.18 
 
 
1.59 
0.80 
0.80 
0.40 
 
2.66 
0.66 
1.33 
0.66 
0.66 
5.32 
 
 
1.33 
0.66 
0.66 
0.33 
 
2.66 
1.33 
1.33 
1.33 
1.33 
2.66 
 
 
1.33 
1.33 
1.33 
2.66 
 
1.56 
0.78 
0.39 
0.39 
0.39 
3.12 
 
 
0.78 
0.78 
0.39 
0.39 
 
1.56 
0.78 
0.78 
0.78 
0.39 
3.12 
 
 
0.78 
0.78 
0.39 
0.39 
 
1 MRSA, methicilin-resistant S. aureus. 
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Signal Peptide                Prosequence (Cathelin)
(+ 8) 26
(+ 7) 29
(+10) 32
(+ 6) 37
(+ 6) 33
(+ 6) 19
(+ 3) 14  
 
 
 
 
FIG. 1. Multiple sequence alignment of chicken fowlicidins with representative 
mammalian cathelicidins. Fowlicidins are aligned with classic cathelicidins (human 
LL37, mouse CRAMP, porcine Protegrin-1, and bovine Indolicidin) and a group of 
distantly related neutrophilic granule proteins (NGP) in the pig (pNGP), cow (bNGP), rat 
(rNGP), and rabbit (P15). Dashes are inserted to optimize the alignment and conserved 
residues are shaded. The positions of four exon boundaries are indicated by vertical lines. 
Two intramolecular disulfide bonds in the cathelin pro-sequence are shown. Also 
indicated are the net positive charge (in parenthesis) and length of each mature 
cathelicidin as underlined. Because NGP proteins may not be cleaved following 
activation, no mature sequences are postulated. Note that chicken fowlicidins share 
higher sequence homology with NGP proteins in the first three exons than with classic 
mammalian cathelicidins. 
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FIG. 2. Genomic organization of the chicken fowlicidin cluster (A) and comparative 
analysis of the mammalian cathelicidin gene clusters (B). The continuous genomic 
contig containing chicken fowlicidins was obtained by annotation of three whole-genome 
shortgun sequences (AADN01005055, AADN01005056, and AADN01081708) and 
additional genomic sequences obtained by PCR and vectorette PCR (see “Experimental 
Procedures”). The direction of transcription of each gene is indicated by the arrow. In 
Panel A, the chicken cathelicidin cluster consists of three fowlicidin genes each 
containing four exons (E) shown as solid rectangles. Located between fowlicidin-1 and 
fowlicidin-2 genes is chicken CamKV gene, which is homologous to vesicle-associated, 
calmodulin kinase-like kinase (NP_076951). In Panel B, relative position of each gene is 
indicated by a solid rectangle or vertical line. Note that chicken fowlicidins, similar to 
neutrophilic granule proteins (NGP), are located closely adjacent to an evolutionarily 
conserved gene (KLHL18), but a NGP-like protein is missing in the dog or human 
genome. 
 
Fowlicidin-1 CamKV Fowlicidin-2 Fowlicidin-3
AADN01081708                                             AADN01005055            AADN01005056
PCR Vectorette PCR PCR
Chicken 2p (17 kb)
Mouse 9qF2 (649 kb)
Human 3p21 (942 kb)
Tel
KLHL18  Cathelicidin
Tel
Tel
A
B
Dog 20 (795 kb)
Rat  8q32 (645 kb)
Tel
Tel
Ngp
100 kb             
E1           E2 E3 E4                            E1          E2 E3      E1                     E2 E3    E4                 E4 E3 E2            E1
200 bp
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Fig. 3 
 
 
 
FIG. 3. Phylogenetic analysis of cathelicidins. The tree was constructed by the 
neighbor-joining method based on the proportion difference (p-distance) of aligned 
amino acid sites of the full-length peptide sequences. A total of 1000 bootstrap replicates 
were used to test the reliability of each branch. Numbers on the branches indicate the 
percentage of 1000 bootstrap samples supporting the branch. Only branches supported by 
a bootstrap value of at least 50% are shown. The tree constructed with the peptide 
sequences from the first three conserved exons is essentially the same as the one 
constructed with the full-length peptides, and therefore, is not shown. 
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FIG. 4. Antibacterial properties of fowlicidins.  E. coli ATCC 25922 was incubated with 
peptides in 10 mM phosphate buffer, pH7.4 at 37oC and surviving bacteria were plated onto 
trypticase soy agar plates and quantitated as CFU/ml following overnight incubation. A, dose-
dependent killing of E. coli by fowlicidins and an ovine cathelicidin (SMAP-29). Bacteria were 
exposed to indicated peptide concentrations for 2 h followed by quantitative CFU assays. The 
MIC90 value is indicated as a dotted line. B, Time-dependent killing of E. coli by peptides at 
MIC90 concentrations. Following exposure to peptides (0.1 µM fowlicidin-1, 0.16 µM fowlicidin-
2, and 0.1 µM SMAP-29) or an equal volume of 0.01% acetic acid (control) for 0, 5, 10, 15, 20, 
30, and 60 min, surviving bacteria were plated and counted. C, Effect of Salinity on the 
antibacterial activity of fowlicidins. E. coli were exposed to peptides (0.1 µM fowlicidin-1 and 
0.16 µM fowlicidin-2) or an equal volume of solvent (control) in 10 mM phosphate buffer with 
addition of different concentrations of NaCl (0, 25, 50, 100, and 150 mM). Data shown are means 
± SEM of 2-4 independent experiments.  
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FIG. 5. Cytolytic activities of fowlicidins.  A, hemolytic activity of fowlicidins and SMAP-29 to 
chicken erythrocytes. B, hemolytic activity of fowlicidins and SMAP-29 to human erythrocytes. 
In panels A and B, freshly isolated red blood cells were incubated with different concentrations of 
peptides in PBS for 2 h before measuring the absorbance at 405 nm for the released hemoglobin. 
C, cytotoxicity of fowlicidins and SMAP-29 to MDCK cells. Cells were incubated with serially 
diluted peptides for 24 h in serum-free medium, followed by measurement of the viability of cells 
by an alamarBlue dye-based, colorimetric method. The EC50 values are indicated as dotted lines. 
Data shown are means ± SEM of 2-3 independent experiments.  
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FIG. 6. Neutralization of LPS by fowlicidins. A, LPS binding by fowlcidins. 
Chromogenic Limulus amebocyte lysate assay was used to evaluate the binding of 
fowlicidins to LPS from E. coli O111:B4. The EC50 value is indicated as a dotted line. 
Data shown are means ± SEM of three independent experiments. B, Hill plot of LPS 
binding by fowlicidins showing the binding affinity. The plot was graphed from the 
means in panel A. The Hill’s coefficient was derived from the slope of the linear 
regression. C, Blockage of LPS-induced IL-1β gene expression by fowlicidins. D, 
Blockage of LPS-induced CCL-2/MCP-1 gene expression by fowlicidins. In panels C and 
D, RAW264.7 cells were pretreated for 30 min with increasing concentrations (1, 5, and 
20 µM) of peptides, and then stimulated with 100 ng/ml LPS or left untreated for 4 h. 
Total RNA was isolated from cells and subjected to real time RT-PCR. Data shown are a 
representative of two independent experiments with similar results. 
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5.1    Summary  
  
Cationic antimicrobial peptides are naturally occurring antibiotics that are actively 
being explored as a new class of anti-infective agents. We recently identified three 
cathelicidin antimicrobial peptides from chicken with potent and broad-spectrum 
antibacterial activities in vitro (Xiao Y, Cai Y, Bommineni YR, Fernando SC, Prakash O, 
Gilliland SE & Zhang G. 2006. J Biol Chem 281, 2858-2867). Here we report that 
fowlicidin-1 mainly adopts an α-helical conformation with a slight kink induced by 
glycine close to the center, in addition to a short flexible unstructured region near the N-
terminus. To further gain insight into the structural requirements for function, a series of 
truncation and substitution mutants of fowlicidin-1 were synthesized and tested 
separately for their antibacterial, cytolytic, and lipopolysaccharide (LPS)-binding 
activities. The short C-terminal helical segment after the kink, consisting of a stretch of 
eight amino acids (residues 16 to 23), was shown to be critically involved in all three 
functions, suggesting that this region may be required for the peptide to interact with LPS 
and lipid membranes and to permeabilize both prokaryotic and eukaryotic cells. We also 
identified a second segment comprised of three amino acids (residues 5 to 7) in the N-
terminal flexible region that participate in LPS binding and cytotoxicity, but are less 
important in bacterial killing. The fowlicidin-1 analog with deletion of the second N-
terminal segment (residues 5 to 7) was found to retain substantial antibacterial potency 
with a significant reduction in cytotoxicity. Such a peptide analog may have considerable 
potential for development as an anti-infective agent. 
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5.2    Introduction  
 
Cathelicidins are a major family of animal antimicrobial peptides with hallmarks of a 
highly conserved prosequence (cathelin domain) and an extremely variable, 
antibacterially active sequence at the C-terminus [1-3]. The exact microbicidal 
mechanism for this family of antimicrobial peptides is not clearly understood. However, 
it is generally believed that the electrostatic interaction between the C-terminal cationic 
peptides with anionic lipids followed by membrane permeabilization is mainly 
responsible for killing prokaryotic cells. Because of such a non-specific membrane-lytic 
mechanism, many cathelicidins kill a variety of bacteria at low micromolar 
concentrations with much less chance of developing resistance [4-6]. More importantly, 
they are equally active against antibiotic-resistant bacterial strains with some 
demonstrating synergism in killing bacteria with conventional antibiotics or structurally 
different antimicrobial peptides [7-9]. One side-effect that is commonly associated with 
cathelicidins as potential therapeutic agents is their cytotoxicity toward mammalian host 
cells [4-6]. However, the concentrations that are required for cathelicidins to exert an 
appreciable cytolytic effect are often higher than the bactericidal concentrations. 
Structure-activity relationship (SAR) studies of cathelicidins revealed that cationicity, 
amphipathicity, hydrophobicity, and helicity (helical content) are among the most 
important determinants of their microbicidal and cytolytic activities [10, 11]. However, in 
general there is no simple correlation between any of these physicochemical properties 
and peptide functions. A delicate balance of these parameters often dictates the 
antimicrobial potency and target selectivity [10, 11]. Moreover, the domain that is 
responsible for cytotoxicity can sometimes be separated from that for antimicrobial 
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activity [12, 13]. Therefore, it is possible that strategic manipulation of structural and 
physicochemical parameters of cathelicidins may maximize their antimicrobial activity 
while reducing their cytotoxicity.  
We and others have recently identified three novel chicken cathelicidins [14-16], 
which are called fowlicidins 1-3 in this report. All three fowlicidins share little similarity 
with mammalian cathelicidins in the C-terminal sequence [16]. Putatively mature 
fowlicidin-1, a linear peptide of 26 amino acid residues, was found to be broadly active 
against a range of Gram-negative and Gram-positive bacteria with a similar potency to 
SMAP-29 [16]. However, fowlicidin-1 also displayed considerable cytotoxicity toward 
human erythrocytes and mammalian epithelial cells with 50% lysis in the range of 6-40 
µM [16].  
To better understand its mechanism of action, we determined its tertiary structure by 
NMR spectroscopy in this study. Fowlicidin-1 was shown to be composed of an α-helical 
segment with a slight kink near the center and a flexible unstructured region at the N-
terminal end. A series of deletion and substitution mutants of fowlicidin-1 were further 
synthesized and tested separately for their antibacterial, LPS-binding, and cytolytic 
activities. The regions that are responsible for each of these functions have been revealed. 
In addition, we identified a fowlicidin-1 analog with deletion of the N-terminal flexible 
region that retains the antibacterial potency but with substantially reduced cytotoxicity. 
Such a peptide analog may represent an excellent candidate as a novel antimicrobial 
agent against bacteria that are resistant to conventional antibiotics.  
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5.3    Results  
 
Solution structure of fowlicidin-1 
 
To first determine the secondary structure of fowlicidin-1, CD spectroscopy was 
performed in the increasing concentrations of structure-promoting agents, 
trifluoroethanol (TFE) and SDS. As shown in Fig. 1A, fowlicidin-1 was largely 
unstructured in the aqueous solution, but underwent a dramatic transition to a typical α-
helical conformation with addition of TFE. The α-helical content of fowlicidin-1 
increased dose-dependently from 10% in 50 mM phosphate buffer to 81% in 60% TFE, 
with a concomitant reduction of the random coiled structure.  Significant α-helical 
content (81%) was similarly observed in the presence of 0.25% or 0.5% SDS (Fig. 1B). 
Because of adoption of a well-defined structure in the presence of TFE or SDS, 
subsequent NMR experiments were done in 50% deuterated TFE. The spectra acquired at 
35oC gave good chemical shift dispersion with limited spectral overlap, enabling the 
assignment of most spin systems for fowlicidin-1 (Table S1, Figs. S1 and S2). The 
complete proton resonance assignments were obtained for the peptide using spin system 
identification and sequential assignments [17] from 2D NMR spectra recorded at 35oC.  
Some ambiguities due to overlapping signals were also solved by the comparative use of 
spectra recorded at 10ºC and 35ºC. In these assignments, Hα(i)-Hδ(i+1:Pro) (dαδ) or Hα(i)-
Hα(i+1:Pro) (dαα) NOEs instead of dαN were used for Pro7, which showed strong dαδ 
NOEs, indicating that Pro7 in fowlicidin-1 has trans configuration. 
Stereo-specific assignments of β-methylene protons were obtained by using 
information on 3JHαHβ coupling constants estimated qualitatively from short-mixing time 
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TOCSY spectra combined with intra-residue NH-Hβ and Hα-Hβ NOEs. Qualitative 
analysis of short- and medium-range NOEs, 3JHNHα coupling constants, and slowly-
exchanging amide proton patterns was used to characterize the secondary structure of 
fowlicidin-1. The sequential and medium distance NOEs connectivities as well as Cα-
proton chemical shift index (∆CαH) [18] are illustrated in Fig. 2 . A number of 
nonsequential dαN(i, i+3) and dαβ(i, i+3) NOEs that are clearly characteristics of α-helical 
conformation were observed for fowlicidin-1 from Leu8 to Lys25. A continuous stretch of 
dNN(i, i+1) also extended from Leu8 to Lys25, except for Gly16. The helicity of fowlicidin-
1 was further supported by the chemical shift index (Fig. 2).     
To determine the tertiary structure of fowlicidin-1, a total of 247 NOE distance 
constraints involving 90 interresidue, 81 sequential, and 76 medium range constraints 
were used in structural calculations (Table 1). Of 100 conformers calculated, 20 
structures with the lowest energy were retained for further analysis. All 20 structures 
were in good agreement with the experimental data, with no distance violations > 0.3 Å 
and no angle violations > 5°. A Ramachandran plot was also produced by PROCHECK-
NMR [19] showing that 76.1% of the residues are in the most favored region and 21.8 
and 1.1% in additional and generously allowed regions, respectively (Table 1).  
The minimized average structure is shown in Fig. 3A, indicating that fowlicidin-1 is 
primarily an α-helical peptide consisting of a helical segment from Leu8 to Lys25 and a 
disordered region near the N-terminus from Arg1 to Pro7. No unambiguous long range 
NOEs for the first four N-terminal residues were observed (Fig. 2), indicative of their 
extremely flexible nature. A closer examination revealed that the long helix of 
fowlicidin-1 is further composed of two short, but perfect, α-helical segments (Leu8-Ala15 
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and Arg21-Lys25) with a slight bend between Gly16 and Tyr20, due to the presence of Gly16 
(Fig. 3A). A superimposition of the backbones of 20 lowest energy structures best fitted 
to residues 8-16 or residues 17-25 indicated that the two short helices are highly rigid, but 
with some degree of flexibility in between (Fig. 3B and 3C). The superimposition of the 
two short helical segments of the 20 final structures against an averaged structure resulted 
in a RMSD value of backbone < 0.5 Å (Table 1). Greater flexibility between the helices 
was revealed when only one segment of the helix was superimposed (Table 1).  It is 
noteworthy that the angle between the two helical axes could not be measured because of 
a lack of NOEs in the Gly16 region and fluidity between the two segments. However, 
flexibility of the “hinge” is somewhat restricted by the side chains of nearby residues, 
such as Tyr17 (Fig. 3A). 
 
Design and physicochemical properties of fowlicidin-1 analogs 
 
 
In contrast with most cathelicidins containing a highly cationic, amphipathic α-helix 
[10], the central helical region (residues 6-23) of fowlicidin-1 is highly hydrophobic, 
containing only two cationic residues (Arg11 and Arg21) and two uncharged polar residues 
(Thr12 and Gln18) (Fig. 4A). Positively charged residues are instead highly concentrated at 
both ends. To probe the impact of N- and C-terminal cationic regions and two short 
helical segments on antibacterial, LPS-binding, and cytolytic activities of fowlicidin-1, 
several N- and C-terminal deletion mutants were designed (Table 2). All mutants have 
fewer net positive charges than the parent peptide, in addition to missing one or two 
structural components.  
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 To further investigate the influence of helicity on the functional properties, Gly16 of 
fowlicidin-1 was replaced with a helix-stabilizing residue, leucine, to give rise to 
fowlicidin-1-L16. Such a variant minimized the bend and flexibility between two short 
helices as modeled by Modeller [20] (data not shown), without significantly altering any 
other structural or physicochemical characteristics. Another substitution variant, 
fowlicidin-1-K7L12K14L16K18, was designed mainly for significant augmentation of its 
amphipathicity. This mutant now has cationic residues clearly aligned along one side and 
hydrophobic residues aligned along the opposite side of the helix (compare Fig. 4A with 
4B). The net charge of this mutant has increased from +8 to +11, as compared with the 
parent peptide. Replacement of two helix-breaking residues, Pro7 and Gly16, with helix-
stabilizing residues, lysine and leucine, respectively, also enhanced the helical content of 
fowlicidin-1-K7L12K14L16K18 by concomitant reduction of the kink in the center and 
extension of the helix at the N-terminus. Along with simultaneous enhancement of 
amphipathicity, cationicity, and helicity, it is understandable that such a peptide variant 
also has reduced hydrophobicity in the helical region as a result of incorporation of 
several positively charged residues. Consistent with the modeling results, two substitution 
mutants showed increased α-helical contents in the presence of 50% TFE by CD 
spectroscopy, relative to the parent peptide (data not shown). 
 All peptides were synthesized commercially by the standard solid-phase method and 
ordered at >95% purity. The molecular mass and purity of each synthetic peptide were 
further confirmed by mass spectrometry (Table 2). 
 
Antibacterial activities of fowlicidin-1 and its analogs 
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Two representative Gram-negative bacteria (Escherichia coli ATCC 25922 and 
Salmonella enterica serovar Typhimurium ATCC 14028) and two Gram-positive bacteria 
(Listeria monocytogenes ATCC 19115 and Staphylococcus aureus ATCC 25923) were 
used to test antibacterial potency of fowlicidin-1 and its analogs by a modified broth 
microdilution assay as described [16, 21]. As compared with the parent peptide, the 
analog with deletion of three C-terminal lysines [fowlicidin-1(1-23)] or four N-terminal 
residues [fowlicidin-1(5-26)] or seven N-terminal residues [fowlicidin-1(8-26)] retained 
much of the bactericidal activity (Table 3), suggesting that the cationic residues at both 
ends are dispensable for its antibacterial activity, but all or part of the central 
hydrophobic α-helical region between residues 8-23 plays a major role in killing bacteria. 
However, the peptide analog that is composed of entirely the central hydrophobic α-helix 
(residues 8-23) with a net charge of +2 became insoluble in 0.01% acetic acid and, 
therefore, was excluded from antibacterial assays. 
To further examine the differential role of the N- and C-terminal short helical 
segments in antibacterial potency, fowlicidin-1(1-15) with omission of the C-terminal 
helical region after the kink at Gly16, was tested against the four bacterial strains and 
found to have only < 2-fold reduction in minimum inhibitory concentration (MIC) toward 
Gram-negative bacteria, but 7- to 18-fold reduction toward Gram-positive bacteria (Table 
3), suggesting that the C-terminal short helix (residues 16-23) is critical in maintaining its 
antibacterial potency against Gram-positive but not Gram-negative bacteria. This is 
consistent with earlier observations that activity of cationic antimicrobial peptides against 
Gram-negative bacteria is generally more tolerant to structural changes [10]. 
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In contrast to our expectations, two substitution mutants (fowlicidin-1-L16 and 
fowlicidin-1-K7L12K14L16K18) with significant improvement in helicity, amphipathicity, 
and/or cationicity were found to have reduced antibacterial activity, relative to the wild-
type peptide (Table 3), reinforcing the notion that an intricate balance, rather than a 
simple enhancement in those structural parameters, dictates the antibacterial potency of 
the α-helical antimicrobial peptides [10, 11]. It is noteworthy that all peptide analogs 
showed similar kinetics in killing bacteria as the full-length peptide, with maximal 
activities being reached 30 min after incubation with bacteria in the presence or absence 
of 100 mM NaCl (data not shown). It is not clear why fowlicidin-1-K7L12K14L16K18 
largely maintained its potency against S. aureus and Salmonella enterica serovar 
Typhimurium, but failed to completely inhibit the growth of E. coli and L. 
monocytogenes even at the highest concentration (7.6 µM = 25 µg/ml) that we tested. 
 
Cytotoxicity of fowlicidin-1 and its analogs 
 
To map the region that is responsible for lysis of eukaryotic cells and to identify a 
peptide analog with reduced cytolytic activity, all deletion and substitution mutants of 
fowlicidin-1 were tested individually against human erythrocyte and Madin-Darby canine 
kidney cells (MDCK) for their toxicity as previously described [13, 16, 22]. As 
summarized in Table 3, Fowlicidin-1 exhibited considerable toxicity toward erythrocytes 
and epithelial cells with 50% effective concentrations (EC50) in the range of 6-15 µM. 
Deletion of the last three lysines [fowlicidin-1(1-23)] resulted in a modest < 4-fold 
reduction in toxicity, while truncation of the entire C-terminal short helix [fowlicidin-1(1-
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15)] caused a nearly complete loss of lytic activity toward both erythrocytes and 
epithelial cells, indicating that the C-terminal helix (residues 16-23), but not the last three 
lysines, is a critical determinant of cytotoxcity. 
Relative to the full-length peptide, fowlicidin-1(5-26) maintained a similar lytic 
activity, whereas fowlicidin-1(8-26) only caused minimal 20% lysis of human red blood 
cells at 360 µM, the highest concentration tested (data not shown), suggesting possible 
presence of another cytotoxicity determinant in the N-terminal unstructured segment 
between residues 5-7. Consistent with these results, a significant >10-fold reduction in 
killing MDCK cells was also observed with fowlicidin-1(8-26) (Table 3). Because of the 
fact that two peptide analogs, fowlicidin-1(1-15) and fowlicidin-1(8-26) each containing 
one cytolytic determinant, had substantially reduced toxicity, it is likely that the two lytic 
sites (residues 5-7 and 16-23) act in a synergistic manner in lysis eukaryotic cells, i.e., the 
presence of one determinant facilitates the action of the other. 
Single substitution of Gly16 for leucine (fowlicidin-1-L16) did not lead to any obvious 
alterations in killing eukaryotic cells (Table 3). In contrast, fowlicidin-1-K7L12K14L16K18 
with a nearly perfect amphipathic helix in the center showed a 6-fold increase in lysis of 
red blood cells, but only slightly higher lytic activity against mammalian epithelial cells 
(Table 3). This suggested that the amphipathic helix has a stronger binding affinity and 
permeability toward erythrocyte membranes than to epithelial membranes, perhaps due to 
the difference in the lipid composition of the two host cell types. 
 
LPS-binding activity of fowlicidin-1 and its analogs 
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Binding and disrupting anionic LPS, the major outer membrane component of Gram-
negative bacteria, is often the first step for antimicrobial peptides to interact with bacteria 
and permeabilize membranes [10]. Several cathelicidins, including human LL-37/hCAP-
18 [21, 23], rabbit CAP-18 [24], and sheep SMAP-29 [25], have been shown to bind and 
neutralize LPS with EC50 at low micromolar concentrations. We have also demonstrated 
that fowlicidin-1 has at least two LPS binding sites [16]. To map the regions involved in 
the binding of fowlicidin-1 to LPS, the N- and C-terminal deletion mutants were mixed 
with LPS, and their ability to bind LPS and inhibit LPS-mediated procoagulant activation 
was measured by a chromogenic Limulus amoebocyte assay [21, 25]. As shown in Fig. 
5A, fowlicidin-1(1-23) and fowlicidin-1(5-26) had similar affinities for LPS to the full-
length peptide, with EC50 in the range of 10-39 µM (Table 3), suggesting that LPS-
binding sites are likely to be located in the central helical region between residues 5-23.  
Residues 5-7 is clearly involved in LPS binding and may constitute the core region of 
one LPS-binding site, because fowlicidin-1(8-26) showed a >15-fold reduction in binding 
to LPS relative to fowlicidin-1(5-26), which had a similar affinity for LPS to the full-
length peptide. The other LPS-binding site is likely located in the C-terminal short helix 
between residues 16-23, because deletion of that region [fowlicidin-1(1-15)] resulted in a 
>25-fold reduction in LPS binding, as compared to fowlicidin-1(1-23) (Fig. 5A, Table 3). 
It is important to note that two LPS-binding sites of fowlicidin-1 are located in the same 
regions where the two cytotoxicity determinants reside. This is perhaps not surprising, 
given that sequences that interact with anionic LPS or phospholipids on bacterial 
membranes are likely involved in interactions with eukaryotic cell membranes, which is a 
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prerequisite for cytotoxicity. In fact, the hemolytic domain of SMAP-29 was also shown 
to overlap with a LPS-binding site at the C-terminal end [25]. 
To determine whether the two LPS-binding sites act in a synergistic manner, an 
equimolar mixture of fowlicidin-1(1-15) and fowlicidin-1(8-26) with each containing one 
LPS-binding site was incubated with LPS and measured for their ability to bind to LPS. 
As shown in Fig. 5A, the mixture displayed an enhanced affinity for LPS, approaching 
the full-length peptide, indicative of the synergistic nature of two LPS-binding sites. Both 
substitution mutants, fowlicidin-1-L16 and fowlicidin-1-K7L12K14L16K18, had minimal 
changes in LPS-binding affinity, relative to the native peptide (Fig. 5B), suggesting that a 
simultaneous enhancement in helicity, cationicity, and amphipathicity has little impact on 
interactions of peptides with LPS and possibly with bacterial membranes as well, which 
may explain why the antibacterial activities of both mutants remained largely unchanged 
(Table 3). 
 
5.4    Discussion  
 
Cathelicidins are highly conserved from birds to mammals in the prosequence, but are 
extremely divergent in the C-terminal mature sequence [1-3]. Cathelicidin-like molecules 
have also been found in the hagfish, the most ancient extant jawless fish with no adaptive 
immune system [26]. With the finding that fowlicidin-1 adopts an α-helix (Fig. 3), it is 
now evident that at least one cathelicidin in α-helical conformation is present in each of 
the fish, bird, and mammalian species examined. This suggests that, in addition to the 
prosequence, cathelicidins appear to be conserved in the mature region structurally and 
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presumably functionally as well. It is plausible that presence of additional structurally 
different cathelicidins in certain animal species may help the hosts better cope with 
unique microbial insults in the ecological niche where each species inhabits, given the 
fact that different cathelicidins appear to possess non-overlapping antimicrobial spectrum 
[6] and that some act synergistically in combinations in killing microbes [7].  On the 
other hand, innate host defense of animal species like primates and rodents containing a 
single cathelicidin may be compensated by the presence of a large number of other 
antimicrobial peptides such as α- and β-defensins [27, 28].  Conversely, pig and cattle 
have multiple cathelicidins but no alpha-defensins reported. 
Our NMR studies revealed that, in addition to a short flexible unstructured region at 
the N-terminus, fowlicidin-1 is primarily composed of two short α-helical segments 
connected by a slight kink caused by Gly16 near the center (Fig. 3). Interestingly, such a 
helix-hinge-helix structural motif is not uncommon for cathelicidins. Mouse cathelicidin 
CRAMP [22], bovine BMAP-34 [29], and porcine PAMP-37 [30] all adopt a helix-hinge-
helix structure with the hinge occurring at the central glycine (Fig. 6). In fact, none of the 
linear, naturally occurring cathelicidins are strictly α-helical. Besides peptides with helix-
hinge-helix structures, a few other linear cathelicidins consist of a N-terminal helix 
followed by non-helical and mostly hydrophobic tails, such as rabbit CAP-18 [31], sheep 
SMAP-29 [25], and bovine BMAP-27 and BMAP-28 [12] (Fig. 6).  
In addition to cathelicidins, a scan of over 150 helical antimicrobial peptides revealed 
that glycine is frequently found near the center and acts as a hinge to increase flexibility 
in many other protein families [10] (Fig. 6). Presence or insertion of such a hinge in the 
helix has been shown in many cases to be desirable, attenuating the toxicity of peptides to 
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host cells while maintaining comparable antimicrobial potency with the peptides having 
no hinge sequences [10, 11]. Mutation of the hinge sequence with a helix-stabilizing 
residue, like leucine, will generally result in an increase in cytotoxicity and in several 
cases antimicrobial potency as well. However, substituting Gly16 of fowlicidin-1-L16 for 
leucine did not enhance antibacterial or cytolytic activity (Table 3), which is likely due to 
the relatively low flexibility of the wild-type peptide. 
A careful comparison of fowlicidin-1 with other α-helical cathelicidins indicated that 
the α-helix (residues 8-23) of fowlicidin-1 is much more hydrophobic and much less 
amphipathic than most of the mammalian cathelicidins (Fig. 6). The positive charges of 
fowlicidin-1 are more concentrated in the non-helical regions at both ends. Because high 
hydrophobicity is often associated with strong cytotoxicity [10, 11], it is perhaps not 
surprising to see that fowlicidin-1 is relatively more toxic than many other cathelicidins. 
Interestingly, fowlicidin-1 structurally more resembles melittin, a helical peptide found in 
honey bee venom that has a curved hydrophobic helix with positively charged residues 
located primarily at the C-terminal end [32] (Fig. 6). Like fowlicidin-1, melittin displays 
considerable antibacterial and hemolytic activities. An attempt to reduce hydrophobicity 
and enhance amphipathicity of the helical region of fowlicidin-1 to make fowlicidin-1-
K7L12K14L16K18 led to a dramatically increased toxicity particularly toward erythrocytes 
with a minimum change in the antibacterial activity against certain bacteria (Table 3). 
This is consistent with an earlier conclusion that an amphipathic helix is more essential 
for interactions with zwitteronic lipid membranes on eukaryotic cells than for anionic 
lipids on prokaryotic cells [33].  
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Our SAR data revealed the regions that are responsible for each of the antibacterial, 
LPS-binding, and cytolytic activities of fowlicidin-1 (Fig. 7). The C-terminal α-helix 
after the kink (residues 16-23), consisting of a stretch of eight amino acids, is required for 
all three functions, suggesting that this region is likely a major site for the peptide to 
interact with LPS and lipid membranes and to permeabilize both bacterial and eukaryotic 
cells. It is not surprising to see the presence of two lipophilic tyrosines (Tyr17 and Tyr20) 
that might be critical in mediating membrane interactions for fowlicidin-1. However, the 
α-helix before the kink at Gly16 is likely to be involved in membrane penetration as well, 
because the minimum length required for a helical peptide to traverse membranes and 
exert antimicrobial and lytic activities is about 11-14 residues [34].  
Another region, comprised of three amino acids in the N-terminal flexible region 
(residues 5-7), is also involved in both LPS binding and cytotoxicity, but not so important 
in bacterial killing (Fig. 7). It is interesting to note that among the three residues in this 
region is Trp6, which is known to have a preference to be inserted into lipid bilayers at 
the membrane-water interface [35, 36]. Because of such membrane-seeking ability, 
inclusion of tryptophan often renders peptides with higher affinity for membranes and 
more potency against bacteria [37, 38]. It is not known why tryptophan is not 
significantly involved in the antibacterial activity of fowlicidin-1. 
It is noteworthy that the N-terminal helix of many cathelicidins plays a major role in 
LPS binding and bacterial killing, while the C-terminal segment is either dispensable for 
antimicrobial activity or more involved in cytotoxicity [12, 25, 39, 40]. However, the C-
terminal helix after the kink of fowlicidin-1 is more important in killing bacteria than the 
N-terminal helix. Such a sharp difference in the distribution of functional domains along 
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the peptide chain between fowlicidin-1 and other cathelicidins is probably because of a 
more pronounced hydrophobic nature of the helix and the presence of an additional 
highly flexible segment at the N-terminus of fowlicidin-1. 
One aim of our study was to identify peptide analog(s) with better therapeutic 
potential. Fowlicidin-1(1-23) and fowlicidin-1(5-26) had only marginal effect on either 
antibacterial potency or cytotoxicity, whereas fowlicidin-1(1-15) exhibited minimal 
toxicity up to 443 µM, but with an obvious decrease in antibacterial activity particularly 
against Gram-positive bacteria, implying less desirable therapeutic relevance of these 
peptide analogs as a broad-spectrum antibiotic. Fowlicidin-1-L16 and fowlicidin-1-
K7L12K14L16K18 also had a more pronounced reduction in antibacterial activity than in 
toxicity, therefore with reduced clinical potential. In contrast, fowlicidin-1(8-26) with the 
N-terminal toxicity determinant (residues 5-7) deleted and the C-terminal antibacterial 
domain (residues 16-23) left unaltered, had a slight reduction in MIC against bacteria, but 
with >10-fold reduction in toxicity toward mammalian epithelial cells and negligible 
toxicity toward erythrocytes (Table 3). Coupled with its smaller size, this peptide analog 
may represent a safer and more attractive therapeutic candidate than the parent peptide. 
Given the fact that fowlicidin-1 is broadly effective against several common bacterial 
strains implicated in cystic fibrosis, including S. aureus, Klebiella pneumoniae, and 
Pseudomonas aeruginosa in a salt-independent manner [16], its analog, fowlicidin-1(8-
26), might prove useful in controlling chronic respiratory infections of cystic fibrosis 
patients. These results also suggested the usefulness of systematic SAR studies in 
improving the safety and target specificity of antimicrobial peptides. 
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5.5    Materials and methods  
 
Peptide synthesis 
 
Fowlicidin-1 was synthesized using the standard solid-phase method by SynPep 
(Dublin, CA) and its analogs were synthesized by either Sigma Genosys (Woodlands, TX) 
or Bio-Synthesis (Lewisville, TX) (Table 1). The peptides were purified through RP-
HPLC and purchased at >95% purity. The mass and purity of each peptide were further 
confirmed by 15% Tris-Tricine polyacrylamide gel electrophoresis (data not shown) and 
by MALDI-TOF mass spectrometry (Table 1) using the Voyager DE-PRO instrument 
(Applied Biosystems, Foster City, CA) housed in the Recombinant DNA/Protein 
Resource Facility of Oklahoma State University. 
 
CD spectroscopy 
 
To determine the secondary structure of fowlicidin-1, CD spectroscopy was 
performed with a Jasco-715 spectropolarimeter using a 0.1-cm path length cell over the 
180-260 nm range as we previously described [41]. The spectra were acquired at 25oC 
every 1 nm with a 2-s averaging time per point and a 1-nm band pass. Fowlicidin-1 (10 
µM) was measured in 50 mM potassium phosphate buffer, pH 7.4, with or without 
different concentrations of TFE (0%, 10%, 20%, 40%, and 60%) or SDS micelles (0.25% 
and 0.5%). Mean residue ellipticity (MRE) was expressed as [θ]MRE (deg.cm2.dmol-1). 
The contents of six types of the secondary structural elements, including regular and 
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distorted α-helix, regular and distorted β-sheet, turns, and unordered structures, were 
analyzed with the program SELCON3 [42].  
 
NMR spectroscopy 
 
2D [1H-1H] NMR experiments for fowlicidin-1 were performed as previously 
described [43, 44]. Briefly, NMR data were acquired on a 11.75T Varian UNITYplus 
spectrometer (Varian, Palo Alto, CA), operating at 500 MHz for 1H, with a 3-mm triple-
resonance inverse detection probe. The NMR sample of fowlicidin-1, consisting of 4 mM 
in water containing 50% deuterated TFE (TFE-d3, Cambridge Isotope Laboratories) and 
10% D2O, was used to record spectra at 10, 20, 30, and 35°C. The spectra acquired at 
35oC were determined to provide the optimal resolution of overlapping NMR resonances. 
These spectra were processed and analyzed using Varian software VNMR Version 6.1C 
on a Silicon Graphics Octane workstation. The invariant nature of the NMR chemical 
shifts and line widths upon 10-fold dilution indicated that fowlicidin-1 was monomeric in 
solution at the concentration used for 2D NMR analysis. A total of 512 increments of 4K 
data points were collected for these 2D NMR experiments. The high digital resolution 
DQF-COSY spectra were recorded using 512 increments and 8K data points in t1 and t2 
dimensions. Sequential assignments were carried out by comparison of cross-peaks in a 
NOESY spectrum with those in a TOCSY spectrum acquired under similar experimental 
conditions. NOESY experiments were performed with 200, 300, 400 and 500 ms mixing 
times. A mixing time of 200 ms was used for distance constraints measurements. The 
NOE cross-peaks were classified as strong, medium, weak and very weak based on an 
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observed relative number of contour lines. TOCSY spectra were recorded by using 
MLEV-17 for isotropic mixing for 35 and 100 ms at a B1 field strength of 7 KHz.  
Water peak suppression was obtained by low-power irradiation of the water peak 
during relaxation delay. The residual TFE methylene peak was considered as reference 
for the chemical shift values. The temperature dependencies of amide proton chemical 
shifts were measured by collecting data from 10o to 35°C in steps of 5°C by using a 
variable temperature probe. All experiments were zero-filled to 4K data points in t1 
dimension and when necessary, spectral resolution was enhanced by Lorenzian-Gaussian 
apodization. 
 
Structure calculations 
 
For structure calculations, NOE-derived distance restraints were classified into four 
ranges: 1.8-2.7, 1.8-3.5, 1.8-4.0 and 1.8-5.0 Å, according to the strong, medium, weak 
and very weak NOE intensities. Upper distance limits for NOEs involving methyl protons 
and non-stereospecifically assigned methylene protons were corrected appropriately for 
center averaging [45]. In addition, a distance of 0.5 Å was added to the upper distance 
limits only for NOEs involving the methyl proton after correction for center averaging 
[46]. The distance restraints were then used to create initial peptide structures starting 
from extended structures using the program CNS (version 1.1) [47]. CNS uses both a 
simulated annealing protocol and molecular dynamics to produce low energy structures 
with the minimum distance and geometry violations. In general, default parameters 
supplied with the program were used with 100 structures for each CNS run. The final 
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round of calculations began with 100 initial structures and 20 best structures with the 
lowest energy were selected and analyzed with MOLMOL [48] and PROCHECK-NMR 
[19]. Structure figures were generated by using MOLMOL. The structures of fowlicidin-
1 analogs were further modeled by using Modeller [20], based on the parent peptide.  
 
Antibacterial assay 
 
Two representative Gram-negative bacteria (E. coli ATCC 25922 and S. enterica 
serovar Typhimurium ATCC 14028) and two Gram-positive bacteria (L. monocytogenes 
ATCC 19115 and S. aureus ATCC 25923) were purchased from ATCC (Manassas, VA) 
and tested separately against fowlicidin-1 and its analogs by using a modified broth 
microdilution assay as described [16, 21]. Briefly, overnight cultures of bacteria were 
subcultured for additional 3-5 h at 37oC in trypticase soy broth to the mid-log phase, 
washed with 10 mM sodium phosphate buffer, pH 7.4, and suspended to 5 × 105 CFU/ml 
in 1% cation-adjusted Mueller Hinton broth (BBL, Cockeysville, MD), which was 
prepared by a 1:100 dilution of conventional strength Mueller Hinton broth in 10 mM 
phosphate buffer. If necessary, 100 mM of NaCl were added to test the influence of 
salinity on antibacterial activity. Bacteria (90 µl) were then dispensed into 96-well plates, 
followed by addition in duplicate of 10 µl of serially diluted peptides in 0.01% acetic acid. 
After overnight incubation at 37oC, the MIC value of each peptide was determined as the 
lowest concentration that gave no visible bacterial growth.  The antibacterial assays were 
repeated at least 3-4 times for each bacterial strain with <2-fold difference in MIC values 
in all cases, and therefore, representative MIC values were tabulated in Table 3.   
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Hemolysis assay 
 
The hemolytic activity of fowlicidin-1 and its mutants were determined essentially as 
described [13, 22]. Briefly, fresh anti-coagulated human blood was collected, washed 
twice with PBS, diluted to 0.5% in PBS, and 90 µl were dispensed into 96-well plates. 
Serial 2-fold dilutions of peptides were added in duplicate to erythrocytes and incubated 
at 37oC for 2 h. Following centrifugation at 800 × g for 10 min, the supernatants were 
transferred to new 96-well plates and monitored by measuring the absorbance at 405 nm 
for released hemoglobin. Controls for 0 and 100% hemolysis consisted of cells suspend 
in PBS only and in 1% Triton X-100, respectively. Percent hemolysis (%) was calculated 
as [(A 405nm, peptide – A 405nm, PBS) / (A405nm, 1% Triton X-100 – A405nm, PBS)] ×100. EC50 of the 
hemolytic activity was defined as the peptide concentration that caused 50% lysis of 
erythrocytes. 
  
Cytotoxicity assay 
 
The toxic effect of fowlicidin-1 and its analogs on mammalian epithelial cells was 
evaluated with MDCK cells by using alamarBlue dye (Biosource) as previously 
described [16]. Briefly, cells were seeded into 96-well plates at 1.5 × 105/well and 
allowed to grow overnight in DMEM containing 10% FBS. Cells were then washed once 
with DMEM, followed by addition of 90 µl of fresh DMEM, together with 10 µl of 
serially diluted peptides in 0.01% acetic acid in triplicate. After incubation for 18 h, 10 µl 
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of alamarBlue dye were added to cells for 6 h at 37oC in a humidified 5% CO2 incubator 
before the fluorescence was read with excitation at 545 nm and emission at 590 nm. 
Percent cell death was calculated as [1 – (Fpeptide – Fbackground)/(Facetic acid – Fbackground)] ×100, 
where Fpeptide is the fluorescence of cells exposed to different concentrations of peptides, 
Facetic acid is the fluorescence of cells exposed to 0.01% acetic acid only, and Fbackground is 
the background fluorescence of 10% alamarBlue dye in cell culture medium without cells. 
Cytotoxicity (EC50) of individual peptides was defined as the peptide concentration that 
caused 50% cell death. 
 
LPS binding assay 
 
The binding of LPS to fowlicidin-1 and its analogs was measured by a kinetic 
chromogenic Limulus amebocyte lysate assay (Kinetic-QCL 1000 kit; BioWhittaker, 
Walkersville, MD) as previously described [21, 25]. Briefly, 25 µl of serially diluted 
peptide were added in duplicate into 25 µl of E. coli O111:B4 LPS containing 0.5 
endotoxin units/ml and incubated for 30 min at 37oC, followed by incubation with 50 µl 
of the amoebocyte lysate reagent for 10 min. The absorbance at 405 nm was measured at 
10 and 16 min after addition of 100 µl of chromogenic substrate, Ac-Ile-Glu-Ala-Arg-p-
nitroanilide. Percent LPS binding was calculated as [(∆D1 – ∆D2 + ∆D3)/ ∆D1] × 100, 
where ∆D1 represents the difference in the optical density between 10 and 16 min for the 
sample containing LPS only, ∆D2 represents the difference in the optical density between 
10 and 16 min for the samples containing LPS and different concentrations of peptides, 
and ∆D3 represents the difference in the optical density between 10 and 16 min for the 
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samples containing different concentrations of peptides with no LPS. EC50 of the LPS-
binding activity was defined as the peptide concentration that inhibited LPS-mediated 
procoagulant activation by 50%. 
  
Protein Data Bank accession code 
 
The atomic coordinates and structure factors of putatively mature fowlicidin-1 have 
been deposited under accession code 2AMN in the Protein Data Bank, Research 
Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ 
(http://www.rcsb.org/).   
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Table 1.  Structural statistics of the 20 lowest energy structures of fowlicidin-1 
 
 
Total NOE constraints 247 
 Intraresidue (|i-j| = 0)   90 
 Sequential (|i-j| = 1)   81 
 Medium Range (|i-j| ≤ 4)   76 
 Constraints/residue  9.5 
 
Energies (kcal.mol-1) 
 Overall  31.76 ± 1.24 
 Bonds  1.46 ± 0.12 
 Angles  18.61 ± 0.39 
 Improper  1.09 ± 0.13 
 van der Waals  5.30 ± 0.96 
 NOE   5.30 ± 0.63 
 
Pairwise RMSDs for residues 1-26 (Å) 
 Backbone  2.98 ± 0.98 
 Heavy atoms  4.48 ± 0.96 
 
RMSDs to mean structure (backbone/heavy atoms) (Å) 
 Residues 1-26  1.76/2.50 
 Residues 8-16  0.28/0.98 
 Residues 17-25 0.48/1.96 
 
Percentage of residues in regions of φ-ψ space 
 Core 76.1% 
 Allowed 21.8% 
 Generously allowed 1.1% 
 Disallowed 0.9% 
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Table 2.  Fowlicidin-1 and its analogs 
 
 
Mass  
Peptide 
 
Sequence 
 
Charge 
 
Length Calculated Observed
Fowlicidin-1(1-26) 
Fowl-1(1-15) 
Fowl-1(1-23)  
Fowl-1(8-26)  
Fowl-1(5-26)  
Fowl-1-L16  
Fowl1-K7L12K14L16K18 
RVKRVWPLVIRTVIAGYNLYRAIKKK 
RVKRVWPLVIRTVIA 
RVKRVWPLVIRTVIAGYNLYRAI 
       LVIRTVIAGYNLYRAIKKK 
    VWPLVIRTVIAGYNLYRAIKKK 
RVKRVWPLVIRTVIALYNLYRAIKKK 
RVKRVWKLVIRLVKALYKLYRAIKKK 
+8 
+4 
+5 
+5 
+5 
+8 
+11 
26 
15 
23 
19 
22 
26 
26 
3141.9 
1807.3 
2758.4 
2220.8 
2603.2 
3199.0 
3271.2 
3141.6 
1807.6 
2757.2 
2220.9 
2600.3 
3197.3 
3271.1 
 
 
 
 
 
 
 
 
 
Table 3. Functional properties of fowlicidin-1 and its analogs 
 
 
Antibacterial Activity 
(MIC, µM) 
Cytolytic Activity  
(EC50, µM) 
 
Peptide  
S. aureus    Listeria    Salmonella    E. coli  Hemolytic  Cytotoxic 
LPS Binding 
Activity 
(EC50, µM) 
Fowlicidin-1(1-26) 
Fowl-1(1-15) 
Fowl-1(1-23) 
Fowl-1(8-26) 
Fowl-1(5-26) 
Fowl-1-L16 
Fowl-1-KLKLK 
0.5 
13.8 
1.1 
2.8 
0.6 
2.0 
1.9 
2.0 
13.8 
2.3 
5.6 
2.4 
3.9 
>7.6 
2.0 
3.5 
2.3 
2.8 
2.4 
2.0 
1.9 
4.0 
6.9 
4.5 
5.6 
4.8 
7.8 
>7.6      
6 
>443 
38 
>360 
11 
3 
1 
15 
>443 
40 
159 
9 
15 
11 
11 
>443 
39 
>260 
10 
9 
6 
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Fig. 1. CD spectra of fowlicidin-1in different concentrations of TFE (A) and SDS 
micelles (B). The CD spectra of the peptides were acquired at 10 µM in 50 mM 
potassium phosphate buffer, pH 7.4, with or without different concentrations of TFE or 
SDS micelles.  
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Fig. 2. Schematic diagram of sequential and medium distance NOE connectivities 
and CαH chemical shift index for fowlicidin 1. The thickness of the bar reflects the 
strength of the NOE connectivities. 
5             10            15             20            25 
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Fig. 3. Solution structure of fowlicidin-1. A, ribbon stereo-diagram of the restrained 
minimized average structure of fowlicidin-1. B, stereo-diagrams of the backbone trace of 
20 lowest energy structures of fowlicidin-1 with residues 8-16 overlaid. C, stereo-
diagrams of the backbone trace of 20 lowest energy structures of fowlicidin-1 with 
residues 17-25 overlaid. This figure was generated with MOLMOL.
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Fig. 4. Helical wheel projections of the central helical regions (residues 6-23) of 
fowlicidin-1 (A) and its substitution mutant, fowlicidin-1-K7L12K14L16K18 (B). The 
representation shows the amphipathic structure of the helical region. Charged residues are 
indicated in black background, and polar uncharged residues are in gray background. The 
mutated residues are circled. Notice a significant enhancement in amphipathicity of the 
mutant peptide relative to the native peptide.   
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Fig. 5. LPS-binding isotherms of the deletion (A) and substitution mutants (B) of 
fowlicidin-1. The EC50 value, indicated by a dotted line in each panel, was defined as the 
peptide concentration that inhibited LPS-mediated procoagulant activation by 50%. In 
panel A, ■, fowlicidin-1(1-26); ○, fowlicidin-1(8-26); ∆, fowlicidin-1(1-15); ▲, 
fowlicidin-1(5-26); ♦, fowlicidin-1(1-23); ●, fowlicidin-1(8-26) + fowlicidin-1(1-15). In 
panel B, ■, fowlicidin-1(1-26); ▲, fowlicidin-1-L16; and ▼, fowlicidin-1-KLKLK. Data 
shown are means ± SEM of three independent experiments. 
 
 
 
0.1 1 10 100
0
20
40
60
80
100
Peptide (µM)
LP
S 
B
in
di
ng
 (%
)
0.5 5 50 500
0
25
50
75
100
Peptide (µM)
LP
S 
B
in
di
ng
 (%
)
A
B
 
 149
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Alignment of representative linear α-helical antimicrobial peptides 
demonstrating the conservation of a kink induced by glycine near the center. 
Putatively mature fowlicidin-1 sequence is aligned with representative cathelicidins 
(mouse CRAMP, rabbit CAP18, bovine BMAP34 and BMAP28 , sheep SMAP34 and 
SMAP29, and porcine PMAP37) as well as three insect peptides (fruit fly cecropin A1, a 
putative porcine cecropin P1, and honey bee melittin). Dashes are inserted to optimize the 
alignment and conserved residues are shaded. Note that each peptide aligned has an α-
helix N-terminal to the conserved glycine (boxed) near the center, followed by either a 
helical or unstructured tail. The only exception is CRAMP, which has a kink at Gly11 
instead of Gly18 [22].  
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Fig. 7. Schematic drawing of the distribution of functional determinants of 
fowlicidin-1. Note that the C-terminal helix from Gly16 to Ile23 is indispensable for 
antibacterial, cytolytic, and LPS-binding activities, whereas the three residues (Val5-Pro7) 
in the N-terminal unstructured region constitute the core of the second determinant that is 
critically involved in cytotoxicity and LPS binding, but less significant in the bactericidal 
activity. The N-terminal helix (Leu8-Ala15) also presumably facilitates the interactions of 
the C-terminal helix (Gly16-Ile23) with lipid membranes. 
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Supplementary material 
 
 
Table S1. Proton chemical shift assignments of fowlicidin 1 in deuterated TFE: H2O 
(1:1) and 35ºC. 
 
Residue HN  Hα  Hβ Other 
Arg1    4.11  1.96 CγH 1.71; CδH 3.23; NH 7.22 
Val2 8.34  4.18  2.08 CγH 0.98 
Lys3 8.11  4.83  1.82, 1.71 CγH 1.49; CδH 1.39; CεH 2.99 
Arg4 8.01  4.31  1.62 CγH 1.41; CδH 3.09; NH 7.08 
Val5 7.60  4.25  2.20 CγH 0.93 
Trp6 7.74  4.75  3.37 Cδ1H 7.26; CεH 3 7.52; Cη2H 7.2; Cζ2H 7.45; Cζ3H 7.09; NH 9.75 
Pro7    4.19  2.30, 1.67 Cγ 1.98; Cδ 3.59 
Leu8 7.23  4.15  1.74 CγH 1.64; CδH 0.94, 0.86 
Val9 7.67  3.62  2.25 CγH 0.99, 0.93 
Ile10 7.86  3.73  1.82 CγH 1.50, 1.21, 0.88; CδH 0.88 
Arg11 7.72  3.96  1.96 CγH 1.89; CδH 3.16; NH 7.07 
Thr12 7.74  3.99  4.44 CγH 1.29 
Val13 8.18  3.72  2.27 CγH 1.06 
Ile14 8.28  3.78  1.94 CγH 1.57, 1.09, 0.96; CδH 0.81 
Ala15 8.27  4.20  1.57  
Gly16 8.27  3.92, 3.90   
Tyr17 8.40  4.38  3.19 CδH 7.11; CεH 6.78 
Asn18 8.30  4.39  2.99, 2.74 NH 7.44, 6.54 
Leu19 8.18  4.18  1.79 CγH 1.69; CδH 0.92 
Tyr20 8.16  4.14  3.15 CδH 7.01; CεH 6.77 
Arg21 7.96  3.82  1.81, 1.66 CγH 1.51; CδH 3.1; NH 7.07 
Ala22 7.76  4.15  1.53  
Ile23 7.94  3.95  1.91 CγH 1.61, 1.24, 0.9; CδH 0.83 
Lys24 7.87  4.16  1.70 CγH 1.59; CδH 1.27; CεH 2.95 
Lys25 7.76  4.24  1.88 CγH 1.70; CδH 1.50; CεH 2.99 
Lys26 7.75  4.26  1.91 CγH 1.73; CδH 1.50; CεH 3.02 
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Fig. S1. Fingerprint region of a 500-MHz 2D [1H, 1H]-TOCSY NMR spectrum of 
fowlicidin-1 in deuterated TFE: H2O (1:1) and 35ºC. 
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Fig. S2. Fingerprint (NH-NH) region of a 500-MHz 2D [1H, 1H]-NOESY NMR 
spectrum of fowlicidin-1 in deuterated TFE: H2O (1:1) and 35ºC. 
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CHAPTER VI 
SUMMARY AND FUTURE PROSPECTS 
 
6.1    Summary  
 
In this dissertation, a brief review of antimicrobial peptides including their features, 
classifications, roles in immunity, mechanisms of action and therapeutic potential were 
discussed. This study focused on the chicken antimicrobial peptides. Chicken β-defensin 
gene cluster was identified and studied by comparative analyses with mammalian 
homologues. Chicken cathelicidins were identified and analyzed for their structures and 
functions. At last one therapeutic candidate was suggested based on the structure-activity 
relationship study of fowlicidin-1. 
 
Following a comprehensive screen, here we report that the chicken genome encodes a 
total of 13 different β-defensins but with no other groups of defensins being discovered. 
These chicken β-defensin genes, designated as Gallinacin 1-13, are clustered densely 
within a 86-Kb distance on the chromosome 3q3.5-q3.7. The deduced peptides varied 
from 63 to 104 amino acid residues in length sharing the characteristic defensin motif. 
Based on the tissue expression pattern, 13 β-defensin genes can be divided into two 
subgroups with Gallinacin 1-7 being predominantly expressed in bone marrow and the 
respiratory tract and the remaining genes being restricted to liver and the urogenital tract. 
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Comparative analysis of the defensin clusters among chicken, mouse, and human 
suggested that vertebrate defensins have evolved from a single β-defensin-like gene or 
gene cluster, which has undergone rapid duplication, diversification, and translocation in 
various vertebrate lineages during evolution. We conclude that the chicken genome 
encodes only β-defensin sequences and that all mammalian defensins are evolved from a 
common β-defensin-like ancestor. The α-defensins arose from β-defensins by gene 
duplication, which may have occurred after the divergence of mammals from other 
vertebrates, and θ-defensins have arisen from α-defensins specific to the primate lineage. 
Further analysis of these defensins in different vertebrate lineages will shed light on the 
mechanisms of host defense and evolution of innate immunity. 
 
A genome-wide computational screen of the entire chicken genome led to 
identification of three novel cathelicidins, namely fowlicidins 1-3. Three fowlicidin genes 
are densely clustered within a 7.5-kb distance on chromosome 2 with each gene adopting 
a four-exon, three-intron structure. Synthetic mature fowlicidin-1 and -2 displayed potent 
and salt-independent activities against a broad range of Gram-negative and Gram-positive 
bacteria including antibiotic-resistant strains, mostly in the range of 0.2-0.6 µM. In 
addition, two cathelicidins demonstrated a strong positive cooperativity in binding LPS. 
More desirably, fowlicidin-1 and -2 showed a low cytotoxicity with 50% lysis of 
erythrocytes and epithelial cells occurring at the concentrations of 10-20 µM. Taken 
together, fowlicidin-1 and -2 are clearly among the most potent cathelicidins that have 
been reported. Broad-spectrum and salt-insensitive antibacterial activities, coupled with 
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potent LPS-neutralizing activity and low cytotoxicity, make fowlicidins excellent 
candidates for novel antimicrobial and anti-sepsis agents. 
 
To further explore the potential of fowlicidin-1 as a therapeutic drug, we studied the 
structure-activity relationship of this peptide. The solution structure of fowlicidin-1 was 
solved by nuclear magnetic resonance (NMR) spectroscopy. Apart from a short flexible 
unstructured region near the N-terminus, fowlicidin-1 mainly adopts a α-helical 
conformation in 50% trifluoroethanol with a slight kink induced by glycine close to the 
center. The long helix of fowlicidin-1 is further composed of two shorter, but perfect, α-
helical segments (Leu8-Ala15 and Arg21-Lys25) with a slight bend between Gly16 and Tyr20, 
due to the presence of Gly16.  
 
To gain insight into the structural requirements for function, a series of truncation and 
substitution mutants were synthesized and tested separately for their antibacterial, 
cytolytic, and lipopolysaccharide (LPS)-binding activities. The short C-terminal helical 
segment after the kink (residues 16-23), consisting of a stretch of eight amino acids, was 
shown to be critically involved in all three functions, suggesting that this region is a 
major site for the peptide to interact with LPS and lipid membranes and to permeabilize 
both prokaryotic and eukaryotic cells.  
 
We also identified a second segment comprised of three amino acid residues (residues 
5-7) in the N-terminal flexible region that participate in LPS binding and cytotoxicity, but 
are less important in bacterial killing. The fowlicidin-1 analog with deletion of the second 
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N-terminal segment was found to retain substantial antibacterial potency with drastic 
reduction in cytotoxicity. The substitution mutant fowlicidin-1-L16 and fowlicidin-1-
K7L12K14L16K18, which showed the significant enhancement of the helicity and 
amphipathicity, respectively, led to a dramatically increased toxicity particularly toward 
erythrocytes with a minimum change in the antibacterial activity, indicating that an 
amphipathic helix is more essential for interactions with lipid membranes on eukaryotic 
cells than for anionic lipids on prokaryotic cells.  A short peptide variant, namely 
fowlicidin-1(8-26), stands out with the highest therapeutic index among all analogs, 
which represents a safer and more attractive therapeutic candidate than the parent peptide. 
Such a peptide analog may hold great promise as a novel antimicrobial agent against 
bacteria that are resistant to conventional antibiotics. 
 
6.2    Challenges and future prospects 
 
Human and animal health has been improved dramatically since the development and 
application of antibiotics. However, the efficacies of antibiotics have declined 
dramatically due to rapid emergence of antibiotic-resistant microbes. The serious public 
health crisis drives the search for novel antibiotic drugs with a less possibility of gaining 
resistance. A growing body of evidence has suggested that cationic antimicrobial peptides 
represent excellent therapeutic candidates against antibiotic-resistant microbes.   
 
Although with potent in-vitro activities, the potency of some antimicrobial peptides 
diminished when they were applied systemically. For example, Gordon et al. reported 
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that a potent antimicrobial peptide tested in rabbit ocular infection models failed to 
exhibit significant activities [1]. Polyphemusin I, a horseshoe crab antimicrobial peptide, 
displayed excellent in-vitro antimicrobial activity with a MIC of <  0.2 µM, but no 
activity was observed in animal models [2].  It is likely that these peptides were cleared 
by host proteases before exerting antibacterial activities when applied in vivo. Stability is 
one of the major barriers to in vivo application of antimicrobial peptides [3]. 
Consequently, modified peptides have been developed to overcome this stability issue. 
For instance, a structure variant of polyphemusin I, with an additional arginine residue 
inserted in the loop region, showed reasonable activity in vivo [2]. A cecropin B analog 
with one amino acid substituted reduced the degradation rate by 5.7-fold than the parent 
peptide [4].  
 
Toxicity is another barrier that may limit the systemic use of antimicrobial peptides [1, 
3]. The optimizations of the physico-chemical parameters such as positive charges, 
amphipathicity, hydrophobicity, and helicity can reduce their cytotoxicity while 
enhancing or remaining the bactericidal activity [5]. Based on the structure information, 
rational designs of antimicrobial peptide analogs offer a valuable tool to overcome the 
toxicity problem. Our approaches to reduce the cytotoxicity of fowlicidin-1 by structure-
based rational design have clearly supported this strategy.  
 
To avoid proteolytic degradation and toxicity of peptides in systemic applications, 
limiting the use of peptides for tropic therapy is an alternative option. For instance, MBI 
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594AN, a modified bovine indolicidin peptide, is developed as a tropic treatment for 
acute acne, which is currently in a phase II clinical trial [1].  
 
Because of the high cost associated with the use of chemically synthesized peptides, 
cost-effective strategies including recombinant protein techniques, transgenic approaches 
make the application of antimicrobial peptides practical. A number of antimicrobial 
peptides have been expressed as fusion proteins in bacteria or adenoviruses. In several 
cases, transgenic plants expressing antimicrobial peptides displayed broad-spectrum 
antimicrobial activities against phytopathogens [6]. Clearly, producing fowlicidins on a 
large scale with the strategies mentioned above will make these potent peptide antibiotic 
possible for medical or agricultural use.  
 
Undoubtedly, antimicrobial peptides with desirable microbicidal activities, favorable 
immunomodulatory functions, and a less possibility to develop resistance make them 
promising therapeutic candidates in controlling infections. Although there are a few 
barriers that are currently limiting their potential as antibiotic agents, a better 
understanding of their mechanisms of action and structure-activity relationships will help 
address questions about safety and efficacy and bring a bright future to them as a new 
generation of antibiotics.  
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